2016N275057_03 CONFIDENTIA L
The GlaxoSmithKline group of companies 204958
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: An open label, randomised, three arm, single dose, multicentre,
parallel group stud y in healthy subjects to compare the
pharmacokinetics of subcutaneous mepolizumab when delivered
as a liquid drug product in a safet y syringe or an auto injector
with a reconstituted l yophilised drug product from a vial
Compound Number: SB240563
Development Phase: III
Effective Date: 10-JUL-2017
Protocol Amendment Number:  03
Author (s):  
Copy right 2
017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited.
PPD
2016N275057_03 CONFIDENTIA L
The GlaxoSmithKline group of companies 204958
2Revision Chronology
GlaxoSmith Kline
Document NumberDate Version
2016N275057_00 2016 -AUG-31 Original
2016N275057_01 2016 -NOV-05 Amendment No. 1
Update to the content of the Device error forms to r eflect consistency  with other data 
captured in similar studies.  Updated withdrawal wording Section 5.4.1.   Removal of 
Cardiovascular and deaths events Section 7.3.1.4. 
2016N275057_02 2016 -NOV-17 Amendment No. 2
Minor changes incorporated throughout th e document as part of the QC step. 
2016N275057_03 2017 -JUL-10 Amendment No.3
Section 7.3.1.4 Cardiovascular and Death Events section has been removed. S ubsequent 
Section 7.3.1.5 “Regulatory reporting requi rements for SAE’s” is assigned S ection 
number 7.3.1.4 to maintain numerical sequence.
PP
D
PPD
PPD
PPD
2016N275057_03 CONFIDENTIA L
204958
4MEDICA L MONITOR/SPON SOR INFORM ATION PA GE
Medical Monitor/SAE C ontact Information: 
Role Name Day Time Phone Number and 
email addressAfter -hours 
Phone/Cell/
Pager 
NumberSite Address
Primary 
Medical 
Monitor Telephone: Cell: GlaxoSmithKl ine
Upper Merion
709 Swedeland 
Road, King of 
Prussia, PA –
19406, USA
Secondary 
Medical 
Monitor Telephone: Cell: GlaxoSmithKline
5 Moore Drive, PO 
Box 13398, 
Research Triangle 
Park (R TP), NC 
27709- 3398, USA
SAE 
contact  
information Medical 
monitor as 
above Telephone: Cell: GlaxoSmithKline
Upper Merion
709 Swedeland 
Road, King of 
Prussia, PA –
19406, USA
Sponsor L egal Reg istered Address: 
GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
person in the territory  will be provided to the relevant regulatory  authority  as part of the 
clinical trial application .
IND No: 006971,          EudraCT No: 2016- 002405 -19
PPD
PPD
PPD
PPD
PPD
PP
D
PPD
PPD
PPD
PP
D
PPD
PPD
PPD
PPD
PP
D
PPD
PPD
2016N275057_03 CONFIDENTIA L
204958
5INVESTIGA TOR PROTOCOL AGREEMENT PA GE
For pro tocol number 204958
Iconfirm agreement to conduct the study  in compliance with the protocol, as amended by  
this protocol amendment.
I acknowledge that I am responsible for overall study  conduct. I agree to personall y 
conduct or supervise the described stu dy.
I agree to ensure that all associates, colleagues and employ ees assisting in the conduct of 
the study  are informed about their obligations. Mechanisms are in place to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
Investigator Address:
Investigator Phone Number:
Investigator Signature Date
2016N275057_03 CONFIDENTIA L
204958
6TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 204958 ........................................................ 9
2.INTRODUCTION .................................................................................................... 14
2.1. Study Rationale .......................................................................................... 14
2.2. Brief Background ........................................................................................ 15
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 16
4.STUDY DESIGN .................................................................................................... 17
4.1. Overall Design ............................................................................................ 17
4.2. Treatment Arms and Duration ..................................................................... 18
4.3. Type and Number of Subjects ..................................................................... 18
4.4. Design Justification ..................................................................................... 19
4.5. Dose Justification ........................................................................................ 20
4.6. Benefit:Risk Assessment ............................................................................ 20
4.6.1. Risk Assessment ......................................................................... 21
4.6.2. Benefit Assessment ..................................................................... 24
4.6.3. Overall Benefit:Risk Conclusion ................................................... 24
5.SELECTION OF STUDY P OPULATION AND WITHDR AWAL CRITERIA ............. 24
5.1. Inclusion Criteria ......................................................................................... 25
5.2. Exclusion Criteria ........................................................................................ 26
5.3. Screening/Baseline/Run -in Failures ............................................................ 28
5.4. Withdrawal/Stopping Criteria ....................................................................... 28
5.4.1. Withdrawal from the study ........................................................... 28
5.4.2. Liver Chemistry Stopping Criteria ................................................ 29
5.4.3. QTc Stopping criteria ................................................................... 29
5.5. Subject and Study Completion .................................................................... 29
6.STUDY TREATMENT ............................................................................................ 30
6.1. Investigational Pro duct and Other Study Treatment .................................... 30
6.2. Medical Devices .......................................................................................... 32
6.3. Treatment Assignment ................................................................................ 32
6.4. Blinding ....................................................................................................... 32
6.5. Packaging and Labeling .............................................................................. 32
6.6. Preparation/Handling/Storage/Accountability .............................................. 32
6.7. Training Session ......................................................................................... 33
6.8. Compliance with Study Treatment Administration ....................................... 33
6.9. Treatment of Study Treatment Overdose .................................................... 34
6.10. Treatment after the End of the Study .......................................................... 34
6.11. Lifestyle and/or Dietary Restrictions ............................................................ 34
6.11.1. Caffeine, Alcohol, and Tobacco ................................................... 34
6.11.2. Activity ......................................................................................... 34
6.12. Concomitant Medications and Non -Drug Therapies .................................... 35
6.12.1. Permitted Medications and Non -Drug Therapies .......................... 35
6.12.2. Prohibited Medications and Non -Drug Therapies ......................... 35
7.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 35
2016N275057_03 CONFIDENTIA L
204958
77.1. Time and Events Table ............................................................................... 37
7.2. Screening and Critical Baseli ne Assessments ............................................ 41
7.2.1. Critical procedures performed at Screening ................................ .41
7.2.2. Critical procedures performed at first treatment visit .................... 42
7.3. Safety ......................................................................................................... 42
7.3.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 42
7.3.1.1. Time period and Frequency for collecting AE 
and SAE information ................................................... 42
7.3.1.2. Method of Detecting AEs and SAEs ........................... 43
7.3.1.3. Follow -up of AEs and SAEs ........................................ 43
7.3.1.4. Regulatory Reporting Requirements for SAEs ............ 44
7.3.2. Pregnancy ................................................................................... 44
7.4. Medical Device Incidents (Including Malfunctions) ...................................... 44
7.4.1. Time Period for Detecting Medical Device Incidents .................... 44
7.4.2. Follow -up of Medical Device Incidents ......................................... 45
7.4.3. Prompt Repo rting of Medical Device Incidents to GSK ................ 45
7.4.4. Autoinjector and safety syringe functionality assessment ............. 45
7.4.5. Returning defective Medical Devices to GSK ............................... 45
7.4.6. Regulatory Reporting Requirements for Medical Device 
Incidents ...................................................................................... 45
7.5. Physical Exams .......................................................................................... 46
7.5.1. Vital Signs .................................................................................... 46
7.5.2. Electrocardiogram (ECG) ............................................................. 46
7.5.3. Clinical Safety Laboratory Assessments ...................................... 46
7.6. Pharmacokinetics ....................................................................................... 48
7.6.1. Blood Sample Collection .............................................................. 48
7.6.2. Sample Analysis .......................................................................... 48
7.7. Pharmacodynamic Markers ........................................................................ 48
7.8. Immunogenicity ........................................................................................... 48
8.DATA MANAGEMENT ........................................................................................... 48
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .49
9.1. Hypotheses ................................................................................................ .49
9.2. Sample Size Considerations ....................................................................... 49
9.3. Data Analysis Considerations ..................................................................... 50
9.3.1. Analysis Populations .................................................................... 50
9.3.1.1. All Treated Subjects Population .................................. 50
9.3.1.2. Pharmacokinetic Population ....................................... 50
9.3.2. Interim Analysis ........................................................................... 50
9.4. Key Elements of Analysis Plan ................................................................... 50
9.4.1. Raw Plasma Concentrations ........................................................ 50
9.4.2. Derived Plasma Pharmacokinetic Parameters ............................. 50
9.5. Primary Analyses ........................................................................................ 51
9.6. Secondary Analyses ................................................................................... 51
9.6.1. Exploratory Analyses ................................................................... 52
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 52
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 52
10.2. Regul atory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 52
10.3. Quality Control (Study Monitoring) .............................................................. 53
2016N275057_03 CONFIDENTIA L
204958
810.4. Quality Assurance ....................................................................................... 53
10.5. Study and Sit e Closure ............................................................................... 54
10.6. Records Retention ...................................................................................... 54
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 55
11.REFERENCES ....................................................................................................... 56
12.APPENDICES ........................................................................................................ 59
12.1. Appendix 1 –Abbreviations and Trademarks .............................................. 59
12.2. Appendix 2 -Liver Safety Required Actions and Follow up
Assessments .............................................................................................. 61
12.3. Appendix 3 -Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of Adverse Events ............................ 63
12.4. Appendix 4 -Definition of and Procedures for Document ing Medical 
Device Incidents ......................................................................................... 69
12.5. Appendix 5 -Modif ied List of Highly Effective Methods for Avoiding 
Pregnancy in FRP and Collection of Pregnancy Information ....................... 71
12.6. Appendix 6 -Anaphylaxis Criteria ............................................................... 73
12.7. Appendix 7 -Inspection of the Autoinjector .................................................. 74
12.8. Appendix 8 -Auto injector Error/Failure reporting form ............................... 75
12.9. Appendix 9 -Inspection of the Safety Syringe ............................................. 78
12.10. Appendix 10 -Safety Syringe Error/ Failure reporting form ......................... 79
12.11. Appendix 11 -Country Specific Requirements ............................................ 82
12.12. Appendix 12 - Pro tocol Amendment Changes 01........................................ 83
12.13. Appendix 13 -Protocol Amendment Changes 02 ...................................... 103
12.14. Appendix 14 -Protocol Amendment Changes 03 ...................................... 112
2016N275057_03 CONFIDENTIA L
204958
91. PROTOCOL SYNOPSIS FOR ST UDY 204958
Rationale
Mepolizumab (SB -240563) is a humanized monoclonal antibody  (IgG1, kappa, mAb) 
that blocks human interleukin -5 (hIL -5) from binding to the IL -5 receptor complex 
expressed on the eosinophil cell surface and thus inhibits signaling. Neutr alization of IL -
5 with mepolizumab reduces blood, sputum and tissue eosinophils, which results in a 
reduction in exacerbations/flares and in the maintenance dose of oral corticosteroids 
(OCS) in various eosinophilic -mediated diseases.
Mepolizumab has been investigated for the treatment of patients with severe eosinophilic 
asthma who have current blood eosinophil levels of 150 cells/μL  or greater, or historical 
blood eosinophil levels (within 12 months) of 300 cells/μL  or greater and history  of 
exacerbations despite high dose inhaled  corticosteroid therap y and an additional 
controller.  It has been recently  approved in a number of markets including the EU (03 
December 2015) and US (04 November 2015). Mepolizumab has also been evaluated in 
subjects with moder ate asthma, FI P1L1/PDGFR -negative h ypereosinophilic sy ndrome 
(HES), eosinophilic esophagitis (EoE) and eosinophilic granulomatosis with poly angiitis 
(EGPA) (i.e. Churg Strauss sy ndrome). 
Mepolizumab for Injection, a sterile, single -use, preservative -free, l yophilized drug 
product formulation (herein referred to as ly ophilized drug product) was used in the 
clinical development programs and is the current marketed presentation for asthma 
(Nucala™).  Before use, each vial of l yophilized drug product must be reconstituted with 
water for injection (WFI) using aseptic techniques. As part of the life cy cle of 
mepolizumab, a l iquid drug product provided as a read y-to-use pre -filled s yringe 
assembled into either a safet ysyringe or an autoinjector, Mepolizumab Injection, has 
been developed. Administration of Mepolizumab Injection (herein referred to as liquid 
drug product in autoinjector or liquid drug product in safet y syringe) will be more 
convenient and may  allow the ultimate goal of patient self -administration. 
In vitro anal ytical data confirms that the liquid and ly ophilised formulations of 
mepolizumab are comparable. Consequentl y the likelihood of clinically significant 
differences in the s ystemic exposure, efficacy  or safet y profile between the liquid drug 
product in the safet y syringe or autoinjector and the ly ophilised powder for reconstitution 
in the vial is considered to be low. However, in addition to demonstration of in vitro 
biochemical comparability, the change in formulation and the change in drug pr oduct 
presentation from a manually  administered reconstituted ly ophile to a liquid 
(administered from a safety  syringe or autoinjector) requires demonstration clinically that 
the relative bioavailability  of the treatments are similar  (I CHQ5E; biopharmaceutical 
comparability ).
The aim of this study  is to provide relative bioavailability  data to support the transition 
from the currentl y marketed presentation of the l yophilised powder for reconstitution to a 
ready-to-use liquid in a pre -filled s yringe assembl ed into either a safet y syringe or an 
autoinjector.  The stud y is intended to demonstrate comparable mepolizumab 
pharmacokinetics following a single subcutaneous (SC) dose administration in healthy  
subjects. Safet y (including immunogenicit y) and tolerabili ty will also be evaluated. Blood 
eosinophil count and device functionalit y will also be explored.
2016N275057_03 CONFIDENTIA L
204958
10Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To compare the pharmacokinetics of 
subcutaneous mepolizumab following 
a single dose of the .liquid drug 
product in safet y syringe with the 
lyophilized drug productMepolizumab PK parameters: 
Cmax, AUC(0-t) and AUC(0- ∞).
To compare the pharmacokinetics of 
subcutaneous mepolizumab following 
a single do se of the liquid drug product 
in autoinjecto r with th e lyophilized 
drug product.Mepolizumab PK parameters: 
Cmax, AUC(0-t) and AUC(0- ∞).
Secondary
To assess additional pharmacokinetic 
parameters following mepolizumab 
subcutaneous administration of the 
liquid drug product in autoinjector or 
the liquid drug product in safet y 
syringe in comparison with the 
lyophilized drug product, as data
permittmax, CL /F, Vd/F, λz, t ½, tlast, 
%AUCex.
To assess the safet y and tolerability of 
mepolizumab following a single SC 
dose of the liquid drug product in  
autoinje ctor or the liquid drug product 
in safet y syringe in comparison with 
the ly ophilised drug productAdverse events (AEs), serious adverse 
events (SAEs), including sy stemic 
reactions and injection site reactions.
Haematology  and Clinical Chemistry
Vital sig ns
12-lead ECG
To assess the immunogenicity  of 
mepolizumab following a single SC 
dose of the liquid drug product in   
autoinjector or the liquid drug product 
in safet y syringe in comparison with 
the ly ophilised drug productFrequency  of positive anti -
mepolizumab binding antibodies and 
neutralizing antibodies
2016N275057_03 CONFIDENTIA L
204958
11Overall Design
This will be a randomised, open label, three arm, single dose, multicentre, parallel group 
study  in health y subjects .  Three different mepolizumab treatments will be administere d: 
a liquid drug product in a safet y syringe (test),
a liquid drug product in an autoinjector (test),
a reconstituted lyophilised drug product from a vial (reference).  
All treatments will be administered SC by a health care professional (HCP).  The stud y 
will compare the pharmacokinetics and safet y of mepolizumab administered as a liquid 
drug product in two different devices with the reconstituted lyophilised drug product. 
Blood eosinophil count and device functionality  will also be explored.  Subjects w ill 
receive 100 mg mepolizumab SC as a single injection. The randomisation will be 
stratified by  body  weight (<70kg , 70-<80kg and ≥80kg). The site of injection will be 
randomised 1:1:1 to the upper arm, abdomen or thigh.   
Each subject will receive a single SC dose of mepolizumab on Day  1 and will continue to 
be followed for 85 day s after drug administration. On Day  1 Subjects will be observed for 
at least 8 hours after drug administration until they  are sent home from the unit.
2016N275057_03 CONFIDENTIA L
204958
12Treatment A rms and Duration
Subjects will be randomised to one of three treatment arms in a 1:1:1 ratio:
100 mg SC of the liquid drug product in safety  syringe
100 mg SC of the liquid drug product in autoinjector
100 mg SC of the reconstituted ly ophilised drug product 
Subjects will receive 100 mg mepolizumab SC as a single injection.  The randomisation 
will be stratified by  body weight (<70kg, 70- <80kg and ≥80kg).  Subjects will also be 
randomised in a 1:1:1 ratio to one of three injection locations: upper arm, abdomen or 
thigh. The selection of administration into the right or left side will be based on the 
preference of the subject or if no pre ference is expressed, the preference of the 
investigator.  
Subjects will be screened within 30 day s before dose administration.
For an y given treatment arm subjects will be resident in the unit from the morning before 
Day 1 (Day  –1) until at least 8 hours after drug administration on Day  1, after which 
subjects will be sent home if deemed appropriate at the discretion of the investigator. The 
study  will include a further 15 outpatient visits at 24h (Day  2), 48h (Day  3) and on Day s 
4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57 and 85 for PK, PD and safet y evaluations. A subject 
will be considered having completed the study  if they  complete the final visit on day  85. 
Each subject will participate in the study  for up to approximately  16 weeks (85 day s after 
drug ad ministration), and will have a screening visit, a single dose treatment period, and a 
follow -up visit. 
Follow -up procedures will be performed on the day  of discharge (Day  85) after the last 
blood sample is collected. 
Type and Number of Subjects
This stud y will be conducted in male and female healthy subjects aged ≥18 y ears old.  
Approximately  243 healthy  subjects will be randomised resulting in at least 216 
completed subjects (approximately  72 for each mepolizumab treatment, 24 per injection 
site). At le ast 27 subjects will be randomised within each of three bod y weight strata 
(<70kg, 70- <80kg and ≥80kg), resulting in at least 9 subjects randomised to each 
mepolizumab treatment within each weight strata and 3 subjects within each 
mepolizumab treatment, we ight strata and injection site. Additional subjects may  be 
enrolled if deemed appropriate to ensure at least 216 completed subjects at the discretion 
of the Sponsor in consultation with the I nvestigator. (i.e. complete Day  85 visit). See 
Table 1.
2016N275057_03 CONFIDENTIA L
204958
13Table 1 Study Design with treatment arms, body  weight ranges and 
injection sites
Number of 
SubjectsSafety Syringe Auto injectorLyophilized 
Form ulationUpper 
Arm
Thigh
Abdomen
Upper 
Arm
Thigh
Abdomen
Upper 
Arm
Thigh
AbdomenBody Weight<70 
kg≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥27
70 –
<80 
kg≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥27
≥80 
kg≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥27
Total ≥27 ≥27 ≥27 243
Analysis
The primary  anal ysis will compare AUC (0-t), AUC (0-∞)and Cmax for each test treatment 
(liquid dru g product in autoinjector or liquid drug product in safet y syringe) to the 
reference (reconstituted lyophilised drug product). The anal ysis for each treatment 
comparison will be conducted excluding the data from the test treatment that is not 
relevant for that comparison. The parameters AUC (0-t), AUC (0-∞)and Cmax will be log e
transformed and anal ysed separately  using a fixed effects model, including treatment 
group and injection site (upper arm, abdomen, thigh) as categorical variables and baseline 
weight as a continuous covariate fitted on the log e scale. Point estimates and associated 
two-sided 90% confidence intervals (CI) willbe constructed for the differences between 
the test and reference treatments on the log escale; these will be back -transformed to 
provide point estimates and two- sided 90% C Is for the ratio of each of the test treatments 
to the reference treatment on the original scale.
Safety  data will be presented in tabular and/or graphical format and summarised 
descriptivel y according to GSK’s Integrated Data Standards L ibrary  (IDSL) standards.  
2016N275057_03 CONFIDENTIA L
204958
142. INTRODUCTION
2.1. Stud y Rationale
Mepolizumab (SB -240563) is a humanized monoclonal antibody  (IgG1, kappa, mAb) 
that blocks human interleukin -5 (hIL -5) from binding to the IL -5 receptor complex 
expressed on the eosinophil cell surface and thus inhibits signalling. Neutralization of IL-
5 with mepolizumab reduces blood and sputum eosinophils, which results in a reduction 
in exacerbations/flares and in the maintenance dose of oral corticosteroids (OCS) in 
various eosinophilic -mediated diseases.
Mepolizumab has been investigated for the treatment of patients with severe eosinophilic 
asthma who have current blood eosinophil levels of 150 cells/μL  or greater, or historical 
blood eosinophil levels (within 12 months) of 300 cells/μL  or greater and history  of 
exacerbations despite high dose inhaled corticosteroid therap y and an additional 
controller. It has been recently  approved in a number of markets including the EU (03 
December 2015) and US (04 November 2015). Mepolizumab has also been evaluated in 
subjects wi th moderate asthma, FI P1L1/PDGFR -negative h ypereosinophilic sy ndrome 
(HES), eosinophilic esophagitis (EoE) and eosinophilic granulomatosis with poly angiitis 
(EGPA) (i.e., Churg Strauss syndrome).  Clinical data for mepolizumab administered by  
the intraven ous(IV), SC or IM routes in a variety of eosinophilic conditions is 
summarised in the Investigators’ Brochure (GlaxoSmithKline Document Number 
CM2003/00010/10).  The liquid drug product is described in the Investigators’ Brochur e 
Supplement ( GlaxoSmithKline Document Number 2016N290279_00).
Mepolizumab for Injection, a sterile, single -use, preservative -free, l yophilized drug 
product formulation (herein referred to as ly ophilized drug product) was used in the 
clinical development program and is the current marketed presentation for asthma 
(Nucala™ ).  Before use each vial of l yophilized drug product must be reconstituted with 
water for injection (WFI) using aseptic techniques. As part of t he life cy cle of 
mepolizumab, a liquid drug product provided as a read y-to-use pre -filled s yringe
assembled into either a safet y syringe or an autoinjector, Mepolizumab Injection, has 
been developed. Administration of Mepolizumab Injection (herein referred to as liquid 
drug product in autoinjector or liquid drug product in safet y syringe) will be more 
convenient and may  allow the ultimate goal of patient self -administration.  Mepolizumab 
Injection has not been previously  administered in man.
In vitro anal ytical data confirms that the liquid and ly ophilised formulations of 
mepolizumab are comparable. Consequentl y the likelihood of clinically significant 
differences in the s ystemic exposure, efficacy  or safet y profile between the liquid drug 
product in safet y syringe or auto injector and the ly ophilised drug product is considered 
to be low. However, in addition to demonstration of in vitro biochemical comparability , 
the change in formulation and the change in drug product presentation from a manually  
administer ed reconstituted ly ophile to a liquid drug product (administered from a safet y 
syringe or autoinjector) requires demonstration clinically  that the relative bioavailability  
of the treatments are similar (ICHQ5E; biopharmaceutical comparability ). A full 
description of the liquid drug product (safet y syringe and autoinjector) is given in the 
2016N275057_03 CONFIDENTIA L
204958
15Investigators’ Brochure Supplement (GlaxoSmithKline Document Number 
2016N290279_00).
The aim of this study  is to provide relat ive bioavailability  data to support the transition 
from the currentl y marketed presentation of the l yophilised drug product to the liquid 
drug product in autoinjector and the liquid drug product in safet y syringe.  The study is 
intended to demonstrate comp arable mepolizumab pharmacokinetics following a single 
subcutaneous (SC) dose administration in healthy subjects. Safet y (including 
immunogenicit y) and tolerability will also be evaluated. Blood eosinophil count and 
device functionality  will also be explor ed.
2.2. Brief Background
Mepolizumab binds with high affinity  to human IL -5 and blocks its binding to and the 
activation of the IL-5 receptor (CD125).
The randomized, multi- centre, placebo -controlled exacerbation studies MEA112997, 
MEA115588 ( Pavord, 2012, Ortega , 2014) and Oral Corticosteroid (OCS) Reduction 
Study  MEA115575 ( Bel, 2014) have demonstrated the efficacy of mepolizumab and 
support the use of mepolizumab 100 mg SC every  4 weeks as an add -on therapy  for the 
treatment of severe eosinophilic asthma. Compared with placebo, mepolizumab has been 
shown to: 
Reduce the rate of clinically  significant exacerbations by  approximately  50%.  These 
results were replicated in studies MEA112997 ( Pavord, 2012) and MEA115588 
(Ortega , 2014).
Reduce the rate of exacerbations requiring hospitalisations and/or Emergency 
Department (ED ) visits, with mean reductions ranging from 32% to 61%.
Produce statistically  significant and/or clinicall y relevant improvements in lung 
function based on forced expiratory  volume in one second (FEV 1), asthma control 
based on Asthma Control Questionnaire (ACQ -5), quality  of life based on St. 
George’s Respiratory  Questionnaire (SGRQ) and clinician and subject- rated overall 
response to therap y in the target population.  
Produce consistent reductions in blood eosinophil levels detected at Week 4 which 
were s ustained for the duration of treatment.
Additional details of the pharmacology , efficacy  and safet y can be found in the 
Investigator Brochure ( GlaxoSmithKline Document Number 2016N290279_00).
2016N275057_03 CONFIDENTIA L
204958
163. OBJECTIVE(S) A ND EN DPOINT(S)
Objectives Endpoints
Primary
To compare the pharmacokinetics of 
subcutaneous mepolizumab following 
a single dose of the .liquid drug 
product in safet y syringe with the 
lyophilized drug productMepolizumab PK parameters: 
Cmax, AUC(0- t) and AUC (0-∞).
To compare the pharmacokinetics of 
subcutaneous mepolizumab following 
a single do se of the liquid drug product 
in autoinjecto r with the ly ophilized 
drug product.Mepolizumab PK parameters: 
Cmax, AUC(0-t) and AUC(0- ∞).
Secondary
To assess addit ional pharmacokinetic 
parameters following mepolizumab 
subcutaneous administration of the 
liquid drug product in autoinjector or 
the liquid drug product in safet y 
syringe in comparison with the 
lyophilized drug product, as data 
permittmax, CL /F, Vd/F, λz , t ½, tlast, 
%AUCex.
To assess the safet y and tolerability of 
mepolizumab following a single SC 
dose of the liquid drug product in  
autoinjector or the liquid drug product 
in safet y syringe in comparison with 
the ly ophilised drug productAdverse event s (AEs), serious adverse 
events (SAEs), including sy stemic 
reactions and injection site reactions.
Haematology  and Clinical Chemistry
Vital signs
12-lead ECG
To assess the immunogenicity  of 
mepolizumab following a single SC 
dose of the liquid drug product in   
autoinjector or the liquid drug product 
in safet y syringe in comparison with 
the ly ophilised drug productFrequency  of positive anti -
mepolizumab binding antibodies and 
neutralizing antibodies
2016N275057_03 CONFIDENTIA L
204958
17Objectives Endpoints
Exploratory
To evaluate mepolizumab 
pharmacod ynamic e ffects on blood 
eosinophil count following a single SC 
dose of the liquid drug product in  
safet y syringe or the liquid drug 
product in autoinjector in comparison 
with the ly ophilised drug productRatio to baseline in blood eosinophil 
count over time
To evaluate safet y syringe and 
autoinjector use & functionalityUser and device errors 
4. STUDY DESIGN
4.1. Overall Design
This will be a randomised, multi -centre, open- label, three arm, parallel- group, single -
dose study  in healthy  subjects.  Three different me polizumab treatments will be 
administered:
a liquid drug product in a safet y syringe (test),
a liquid drug product in an autoinjector (test),
a reconstituted lyophilised drug product from a vial (reference).  
2016N275057_03 CONFIDENTIA L
204958
18All treatments will be administered SC by a he alth care professional (HCP).  The study  
will compare the pharmacokinetics and safet y of mepolizumab administered as a liquid 
drug product in two different devices with the reconstituted ly ophilised drug product. 
Blood eosinophil count and device functiona lity will also be explored.
Subjects will receive 100 mg mepolizumab SC as a single injection. The randomisation
will be stratified by  body weight (<70kg, 70- <80kg and ≥80kg). The site of injection will 
be randomised 1:1:1 to the upper arm, abdomen or thigh.  
Each subject will receive a single SC dose of mepolizumab on Day  1and will be 
observed and blood samples co llected for at least 8 hours post dose until they  are sent 
home from the unit. Subjects will continue to be followed for 85 day s after drug 
administration. 
4.2. Treatment A rms and Duration
Subjects will be randomised to one of three treatment arms in a 1:1:1 r atio:
100 mg SC of the liquid drug product in safety  syringe
100 mg SC of the liquid drug product in autoinjector
100 mg SC of the ly ophilised drug product
Subjects will receive 100 mg mepolizumab SC as a single injection. The randomisation
will be strati fied by  body weight (<70kg, 70- <80kg and ≥80kg). The site of injection will 
be randomised 1:1:1 to the upper arm, abdomen or thigh.  The selection of administration 
into the right or left side will be based on the preference of the subject or if no prefere nce 
is expressed, the preference of the investigator.  
Subjects will be screened within 30 day s before dose administration.
For an y given treatment arm subjects will be resident in the unit from the morning before 
Day 1 (Day  –1) until at least 8 hours aft er drug administration on Day  1, after which 
subjects will be sent home if deemed appropriate at the discretion of the investigator. The 
study  will include a further 15 outpatient visits at 24h (Day  2), 48h (Day  3) and on Day s 
4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57 and 85 for PK, PD and safet y evaluations. A subject 
will be considered having completed the study  if they  complete the final visit on day  85. 
Each subject will participate in the study  for up to approximately  16 weeks (up to 85 day s 
after drug administration), and will have a screening visit, a single dose treatment period, 
and a follow -up visit. 
Follow -up procedures will be performed on the day  of discharge (Day  85) after the last 
blood sample is collected. 
4.3. Type and Number of Subjects
This st udy will be conducted in male and female healthy  subjects aged ≥18 y ears old.  
Approximately  243 healthy  subjects will be randomised resulting in at least 216 
completed subjects (approximately  72 for each mepolizumab treatment, 24 per injection 
2016N275057_03 CONFIDENTIA L
204958
19site). At least 27 subjects will be randomised within each of three bod y weight strata 
(<70kg, 70- <80kg and ≥80kg), resulting in at least 9 subjects randomised to each 
mepolizumab treatment within each weight strata and 3 subjects within each 
mepolizumab treatment, weight strata and injection site. Additional subjects may  be 
enrolled if deemed appropriate to ensure at least 216 completed subjects at the discretion 
of the Sponsor in consultation with the I nvestigator. (i.e. complete Day  85 visit). See 
Table 1 below .
Table 1 Study  Design with treatment arms, body  weight ranges and injection 
sites.
Number of 
SubjectsSafety Syringe Auto injectorLyophilized 
Form ulationUpper 
Arm
Thigh
Abdomen
Upper 
Arm
Thigh
Abdomen
Upper 
Arm
Thigh
AbdomenBody Weight<70 
kg≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥27
70 –
<80 
kg≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥27
≥80 
kg≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥3 ≥27
Total ≥27 ≥27 ≥27 243
4.4. Design Justification
A health y subject population is considered to be s uitable for the evaluation of 
mepolizumab PK comparability  among treatments as all treatments will be administered 
to the same population and any  differences would therefore be detected appropriatel y.  
Health y subjects are considered to be a suitable popul ation for biopharmaceutical PK 
comparability  studies and the data can be extrapolated to other populations ( European 
Medicines Agency , (2010) Guideline on the investigation of bioequivalence.).
Mepolizumab has a prolonged half -life of a pproximately  3 weeks and a crossover design 
would require an extended washout period that would limit recruitment and likely  lead to 
significant drop -outs and is therefore considered inappropriate.  A parallel group design 
in healthy  subjects is the ty pical approach for such studies with monoclonal antibodies 
and has been successfully used for a number of similar products. 
To minimise the impact of potential confounding factors and variabilit y, the study will be 
stratified by  body  weight as this is the mai n covariate of mepolizumab exposure, although 
the effect is not large enough to be clinically  relevant. To investigate the effect of 
2016N275057_03 CONFIDENTIA L
204958
20injection site, mepolizumab will be administered by  the health care provider at one of 
three injection sites (upper arm, ab domen or thigh). In order to prevent bias as well as 
maintain balance in treatment groups, the injection site will be randomised.  Collection of 
PK samples up to Day 85 will ensure that mepolizumab plasma concentration -time 
profile is well described with t he extrapolated portion of AUC0- ∞ well below 20%.  
4.5. Dose Justification
A single mepolizumab dose of 100 mg administered SCis selected in this study  as it is 
the approved therapeutic dose in severe asthma and the anticipated therapeutic dose in 
chronic obs tructive pulmonary disease (COPD).
A higher SC dose of 300 mg is currently being investigated in EGPA and HES patients.  
However, this 300 mg SC dose is delivered as multiple injections (3x100 mg) of the same 
presentation as the reference product in this study  (reconstituted l yophilised powder in a 
vial) and is anticipated to be delivered as 3x100 mg of the liquid formulation.  
Consequently  the assessment of a 100 mg SC dose in this study  is considered appropriate 
to also support the comparability  of the l iquid formulation delivered via a safet y syringe 
or an auto injector to the ly ophilised powder for reconstitution at a dose of 300 mg.
4.6. Benefit:Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with 
mepolizumab (SB -240563) ly ophilised drug product can be found in the Investigator’s 
Brochure (IB). The following section outlines the key  risks, risk assessment and 
mitigation strategy for this protocol based on mepolizumab ly ophilised drug product.  
The safet y profile of the mepolizumab liquid drug product is anticipated to be similar to 
the ly ophilised drug product.  
2016N275057_03 CONFIDENTIA L
204958
214.6.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP)  
Risk of Systemic  Reactions, including 
allergic reactionsBiopharmaceutical products administered 
SC may  elicit s ystemic (e.g. 
hypersensitivity ) and local site reactions.
In the placebo controlled severe asthma 
studies both acute and delay ed sy stemic 
reactions including hy persensitivity  have 
been reported following administration of 
mepolizumab with incidence rates similar 
between mepolizumab and placebo -treated 
subjects:
54/915 subjects or 6% in the 
mepolizumab all doses combined group 
7/263 subjects or 3% in th e 
mepolizumab 100 mg SC group
12/344 subjects or 3%  in the 
mepolizumab  75 mg IV group
20/412 subjects or 5% in the placebo 
group. 
The most common sy mptoms reported with 
any systemic reaction included headache, Daily  monitoring of serious adverse events 
(SAEs) by  medical monitor; regular 
systematic review of AE /SAE data from 
ongoing studies b y the Glaxo SmithKline
(GSK) study team and/or safet y review 
team. 
Customized AE and SAE case report form 
(eDC) utilised for targeted collection of 
information for s ystemic reactions adverse 
events.
Use of Joint NI AID/FAAN 2nd Sy mposium 
on Anaph ylaxis to collect data on reports of 
anaph ylaxis (see Appendix 2 ).
Subjects remain in clinic for up to 8 hours 
following administration of  mepolizumab 
to complete all assessments.
2016N275057_03 CONFIDENTIA L
204958
22Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
rash, pruritus, fatigue, and dizziness. Wh ile 
rare, serious s ystemic reactions including 
anaph ylaxis have been reported.
Systemic reactions reported to date across 
the mepolizumab programme are 
summarized in the IB “Adverse events of 
special interest” section; see also ‘Special 
Warnings and Specia l Precautions for Use’ 
section located in Section 6titled ‘Summary  
of Data and Guidance for the I nvestigator’.
Injection site reactions In the placebo controlled sever e asthma 
(PCSA) studies the incidence of local site 
reactions with SC administration of 
mepolizumab was higher on mepolizumab 
100 mg SC group (21/263 or 8%) compared 
to mepolizumab 75mg IV (10/344 or 3%) or 
placebo (13/412 or 3%). Sy mptoms 
included pain, e rythema, swelling, itching, 
and burning sensation. 
Local injection site reactions reported to 
date across the mepolizumab program are 
summarized in the IB “Adverse events of 
special interest” section; see also Section 6
titled ‘Summary  of Data and Guidanc e for Daily  monitoring of serious adverse events 
(SAEs) by  medical monitor; regular 
systematic review of AE /SAE data from 
ongoing studies b y GSK study  team and/or 
safet y review team. 
Customized AE and SAE case report form 
(in the eDC)  utilized for targeted collection 
of information for local injection site 
reactions adverse events.
2016N275057_03 CONFIDENTIA L
204958
23Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
the Investigator’.
Potential risk of I mmunogenicity Biopharmaceutical products may  elicit anti -
drug antibody  (ADA) and neutralizing 
antibody  (Nab), which have the potential t o 
modulate pharmacokinetic (PK), 
pharmacod ynamic (PD) or produce adverse 
reactions. 
Mepolizumab has low immunogenic 
potential. Both incidence and titer data from 
completed studies demonstrate a low risk 
for loss of efficacy  associated with AEs 
and/or alte red PK/PD.   Immunogenicit y 
data reported to date across the 
mepolizumab development program are 
summarized in the IB; See Section 5.4
‘Clinical Immunogenicity ’ and a summary  
of immunogenicity findings in Section 6
‘Other Potentially  Clinically  Relevant 
Information for the Investigator’.Blood samples will be collected for 
detection of both ADA and Nab.
2016N275057_03 CONFIDENTIA L
204958
244.6.2. Benefit A ssessment
In this stud y, there are no anticipated benefit for the participating subjects since these 
subjects are health y subjects. The autoinje ctor and safet y syringe will however provide a 
more convenient mode of delivery from previous mepolizumab administration and 
potentially  provide patients an option to self -administer mepolizumab at home.
4.6.3. Overall Benefit:Risk Conclusion
Current data from me polizumab preclinical and clinical development indicate the ability  
of mepolizumab to inhibit IL- 5 leading to consistent reduction in blood eosinophils, with 
demonstration of clinical benefit in the treatment of conditions associated with 
eosinophilic inflammation, such as asthma. Data from the Phase III asthma programme 
with mepolizumab demonstrates, compared to placebo, a reduction in asthma 
exacerbations, improvements in asthma control and quality  of life (as measured b y the 
ACQ and SGRQ, respectively ), improvements in lung function and a reduction in oral 
corticosteroid use in those subjects on chronic OCS treatment. To date, the safet y profile 
of mepolizumab has been favourable.  This study  will be conducted in healthy  subjects 
which are not expected to receive benefit from this treatment. The change in drug product 
presentation from a reconstituted ly ophilised drug product in a vial to a liquid drug 
product in an autoinjector or a safet y syringe is not anticipated to alter the overall safety 
profile of mepolizumab.
5. SELECTION OF STUDY P OPULA TION A ND 
WITHDRA WAL CRITERIA
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the GSK investigational product or other study  
treatment that may impact subject eligibility  is provided in the I nvestigator’s Brochure 
(number). 
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
2016N275057_03 CONFIDENTIA L
204958
255.1. Inclusion Criteria
A subject will be eligible for inclusion in this study onl y if all of the following criteria are 
met:
AGE
1.18 years of age and over at the time of signing the informed consent.
TYPE OF SUBJECT AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Health y as determined by the investigator or medically qualified designee based on a 
medical evaluation including medical history , physical examination, vital si gns, 
laboratory  tests, and cardiac monitoring.  A subject with a clinical abnormality  or 
laboratory  parameter(s) which is/are not specifically  listed in the inclusion or 
exclusion criteria, outside the reference range for the population being studied may  
be included onl y if the investigator agrees and documents that the finding is unlikely  
to introduce additional risk factors and will not interfere with the stud y procedures or 
ability  to interpret stud y results.
WEI GHT
3.Body weight 50 kg and body  mass i ndex (BMI) within the range 19.0 -30kg/m2
(inclusive)
SEX
4.Male or Female.
5.A female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative human chorionic gonadotrophin (hCG) test), not lactating, and at least one 
of the fol lowing conditions applies:
a.Non-reproductive potential defined as:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectom y
Documented Bilateral Oophorectom y
Post-menopausal females -refer to Appendix 5 for definition 
b. Subject is of reproductive potential and agrees to follow one of the options listed in 
2016N275057_03 CONFIDENTIA L
204958
26the Modified L ist of Highly Effective Methods for Avoiding Pregnancy  in Females 
of Reproductive Potential (FRP) ( Appendix 5 ) from 30 day s prior to the first dose of 
study  medication and until 16 weeks after the administration of the single dose of 
study  medication.  
INFORMED CONSENT
6. Capable of giving signed informed consent which includes compliance with the 
requirements and restrictions listed in the consent form and in the protocol. The 
subject must be able to understand and communicate in the native language of the 
site, e.g. German in German sites.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INT ERVAL) 
1.ALT  >1.5 xUL N  
2.Bilirubin >1.5xUL N (isolated bilirubin >1.5xULN is acceptable if bilirubin is 
fractionated and direct bilirubin <35%).
3.Current or chronic history of liver disease, or known hepatic or biliary  abnormalities 
(with the exception of G ilbert's s yndrome or as ymptomatic gallstones)
4.QTcF >450 msec
5.Any clinically  relevant abnormality  identified at the screening medical assessment 
(physical examination/medical history), clinical laboratory  tests, or 12- lead ECG.
CONCOMI TANT MEDICATIONS
6.Use of prescription or non -prescription drugs, including vitamins, herbal and dietary  
supplements (including St John’s Wort) within 7 day s (or 14 day s if the drug is a 
potential enzy me inducer) or 5 half -lives (whichever is longer) before the first dose 
of study medication and until study  completion, unless in the opinion of the 
investigator and GSK Medical Monitor the medication will not interfere with the 
study  procedures or compromise subject safet y.
2016N275057_03 CONFIDENTIA L
204958
27REL EVANT HABITS
7.History  of regular alcohol consumpt ion within 6 months of the study  defined as: 
8.An average weekl y intake of >14 units for females and >21 units for males .  One 
unit is equivalent to 8 g of alcohol: a half -pint (~240 ml) of beer, 1 glass (125 ml) of 
wine or 1 (25 ml) measure of spirits.
9.Urinary cotinine levels indicative of smoking or history  or regular use of tobacco- or 
nicotine -containing products within 6 months prior to screening. Limit of 
>500 ng/mL.
10.Involved in an y activities likely  to result in an y significant decrease or increase in
body  weight during the study  period (e.g. ‘crash’ dieting, body building).
CONTRAINDICATIONS 
11.History  of sensitivity  to any  of the stud y medications, or components thereof or a 
history  of drug or other allergy  that, in the opinion of the investigator or Medical 
Monitor, contraindicates their participation.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
12.Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody  test 
result at screening or within 3 months prior to first dose of study  treatment. 
13.A positive test for HIV antibody .
14. Subjects with known, pre-existing helminthes infestation within 6 months prior to 
Day 1.
15.Where participation in the study would result in donation of blood or blood products 
in excess of 500 mL  within 3 months.
16.Thesubject has participated in a clinical trial and has received an investigational 
product within the following time period prior to the first dosing day  in the current 
study : 30 day s, 5 half -lives or twice the duration of the biological effect of the 
inves tigational product (whichever is longer).
17. Exposure to more than four new chemical entities within 12 months prior to the first 
dosing day .
18.A positive pre -study  drug/alcohol screen.
19.A vulnerable subject. Defined as individuals whose willingness to volunteer in a 
clinical trial may  be unduly  influenced by  the expectation, whether justified or not, 
of benefits associated with participation, or of a retaliatory  response from senior 
members of a hierarch y in case of refusal to participate.
20.Subjects who work for the Sponsor, CRO, or one of the study  centres.
2016N275057_03 CONFIDENTIA L
204958
285.3. Screening/Baseline/Run-in Failures
Screen failures are defined as subjects who consent to participate in the clinical trial but 
are never subsequently  randomized. In order to ensure transparent reporting of screen 
failure subjects, meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements, and respond to queries from Regulatory  authorities, a minimal 
set of screen failure information is required including Demograph y, Screen Failur e 
details, Eligibility  Criteria, and Serious Adverse Events (see Section 7.3).
Subjects can be re -screened if they  fail screening following discussion with the GSK 
Medical monitor and Investigator.
5.4. Withdrawal/St opping Criteria
A subject may  withdraw from the study  at any  time at his/her own request, or may  be 
withdrawn at an y time at the discretion of the investigator for safety, behavioural or 
administrative reasons. If a subject withdraws from the study , he/she may request 
destruction of an y samples taken, and the investigator must document this in the site 
study  records . 
5.4.1. Withdrawal from the study
If a subject withdraws from the study  then the assessments in the time and events table 
under Section 7.1  Day 85 Withdraw (WD) column must be performed. A reason for the 
withdrawal from the study must be captured in the eDC.
A subject must be discontinued if any of the following criteria are met:
Withdrawal of consent
Lost to follow -up
A subject will also be withdrawn from the study , in consultation with the medical 
monitor and principal investigator, if an y of the following criteria are met:
Laboratory  parameters: Clinically  important changes in laboratory  parameters 
identi fied
Pregnancy : Positive pregnancy  test (see Section 7.3.2 ). Pregnancy  and pregnancy  
outcomes of subjects exposed to mepolizumab will be followed.
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact the subject and re- schedule the missed visit as soon 
as possible. 
The site must counsel the subject on the importance of maintaining the assigned visit 
schedule and a scertain whether or not the subject wishes to and/or should continue in 
the study . 
2016N275057_03 CONFIDENTIA L
204958
29In cases where the subject is deemed ‘lost to follow up’, the investigator or designee 
must make every  effort to regain contact with the subject (where possible, 3 
telephon e calls and if necessary  a certified letter to the subject’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the subject’s medical record. 
Should the subject continue to be unreachable, only then wil l he/she be considered to 
have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
5.4.2. Liver Chemistry Stopping Criteria
Since this is a single dose study  liver chemistry  stopping criteria do not apply . 
However, in case of liver event fol lowing the single dose of stud y treatment all required 
follow up assessments must be completed. Refer to Appendix 2 for complete guidance.
Liver event is defined as:
ALT≥3xULN
If ALT≥3xUL N AND bilirubin 2xUL N (>35% direct bilirubin) or INR >1.5, 
Report as an SAE.
5.4.3. QTc Stopping criteria
Since this is a single dose study  QTc stopping criteria do not appl y. 
However, the following guideline applies for the protocol-specified ECG and QTc 
evaluations.  
The same QT correcti on formula must be used for each individual subject to 
determine eligibility  and for subsequent evaluations while on the study .  This 
formula may  not be changed or substituted once the subject has been enrolled.
For example, if a subject is eligible for th e protocol based on QTcB , then QTcB must 
be used for subsequent evaluations while on the study .
The QTc should be based on single or averaged QTc values of triplicate 
electrocardiograms obtained over a brief (e.g., 5 -10 minute) recording period.
5.5. Subject an d Study  Completion
A subject will be considered having completed the study  if they  complete the final visit 
on day  85.
The end of the stud y is defined as the last subject’s last visit.
2016N275057_03 CONFIDENTIA L
204958
306. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
Mepol izumab for I njection (also referred to as l yophilised drug product in this protocol) 
will be supplied by  GSK in a 100 mg per vial strength.  Mepolizumab for Injection is a 
sterile, ly ophilized drug product and is presented in 10 mL  Type I glass, stoppered vials. 
The formulation contains sodium phosphate, sucrose and pol ysorbate 80.  The vial will 
be reconstituted with Sterile Water for Injection just prior to use.  F urther details of dose 
preparation and administration can be found in the Clinical I nvestiga tor’s Brochure (CIB) 
and the Study  Reference Manual (SRM).
Mepolizumab I njection (also referred to as liquid drug product in this protocol) will be 
supplied by  GSK as a fixed -dose, full y disposable pre -filled Ty pe I glass s yringe with 
rubber stopper, which is assembled in an aut oinjector or safet y syringe. Mepolizumab 
Injection that is assembled into a safet y syringe (also referred to as liquid drug product in 
safet y syringe in this protocol) will have a back stop and plunger rod to enable manual 
delivery  of the drug product.  Mepolizumab I njection that is assembled into an 
autoinjector (also referred to as liquid drug product in autoinjector in this protocol) will 
enable automated deliver of the drug product under the power of a spring mechanism.  
Both pres entations of Mepolizumab Injection contain 100 mg of mepolizumab in a 1 mL  
volume.  The formulation contains sodium phosphate, citric acid, sucrose, EDTA and 
polysorbate 80.
Study Treatment: Lyophilized Drug 
ProductStudy Treatment: Liquid Drug 
Product
Product name: Mepolizumab (Nucala) (SB -240563) Mepolizumab (Nucala) (SB -240563)
Description of 
Device:N/A Prefilled autoinjector
Prefilled Safety Syringe
Formulation 
description:100 mg/mL mepolizumab following 
reconstitution with 1.2 mL sterile 
water for injection (WFI) with sodium 
phosphate, sucrose, and polysorbate 
80100 mg/mL mepolizumab with sodium 
phosphate, citric acid, sucrose, EDTA 
and polysorbate 80
Dosage form: Sterile, lyophilized powder for 
reconstitutionSterile, liquid formulation
Unit dose 
strength(s)/
Dosage level(s):100 mg/vial 100 mg/mL; 1.0 mL (deliverable)
Route of 
Administration SC injection SC injection
Dosing 
instructions:SC dose in upper arm, abodomen, or 
thigh following reconstitution with 1.2 
mL WFISC dose in upper arm, abdomen or 
thigh  
2016N275057_03 CONFIDENTIA L
204958
31Study Treatment: Lyophilized Drug 
ProductStudy Treatment: Liquid Drug 
Product
Physical 
description: White, uniform, lyophilized cake.  
Clear to opalescent, colourless to 
pale yellow sterile solution after 
reconstitution.Clear to opalescent, colourless to 
pale yellow sterile solution 
Physical 
description of 
device:N/A Autoinjector: Single use, disposable 
autoinjector assembled with the 
prefilled syringe containing the drug 
product. The autoinjector enables 
automatic delivery of the drug product 
under the power of a spring 
mechanism following activation o f the 
device.  Start and end of injection 
clicks inform the user of correct use.  
A plastic needle cover shields the 
needle before and after injection to 
minimise the potential for needle stick 
injuries.
Safety syringe: Single use, 
disposable safety syrin ge. Needle
retracts into guard which locks.
Manufacturer/
source of 
procurement:Lyophilized Drug product is 
manufactured at GSK, Parma, ItalyPrefilled syringe : Prefilled syringe 
components are procured from 
Becton Dickinson.  Prefilled syringe is 
filled with drug product and 
assembled at GSK, Barnard Castle, 
UK.
Autoinjector: The autoinjector 
components are manufactured by 
Ypsomed AG and assembled with the 
prefilled syringe at GSK, Barnard 
Castle, UK.
Safety syringe: supplied pre -filled 
with drug. Comp onents are procured 
by Becton Dickinson.  Product 
assembled at GSK, Barnard Castle, 
UK.
2016N275057_03 CONFIDENTIA L
204958
326.2. Medical Devices
The GSK manufactured medical devices (or devices manufactured for GSK by  a third 
party ) provided for use in this study  are injection devices: a prefil led s yringe contained 
within an autoinjector or a prefilled s yringe within a safet y syringe. The devices used in 
the study  are representative of the devices planned to be marketed for the product.
The components that comprise the prefilled s yringe, includi ng glass barrel with prestaked 
needle and stopper are sourced from Becton Dickinson.  The prefilled s yringe is filled 
and assembled at GSK Barnard Castle.  The prefilled sy ringe is assembled with safet y 
syringe device components at GSK Barnard Castle. The safet y syringe components are 
also sourced from Becton Dickinson.
The autoinjector components are manufactured b y Ypsomed AG.  The auto injector 
components are assembled with the prefilled s yringe at GSK Barnard Castle.
The instructions for use (IFU) of th ese injection devices are provided in the SRM .The 
instructions were developed and optimized as a result of formative human factors studies.
GSK medical device incidents, including those resulting from malfunctions of the device, 
must be detected, document ed, and reported by the investigator throughout the study –
see Section 7.4.
6.3. Treatment A ssignment
Subjects will be assigned to one of the three treatments, reconstituted ly ophilised powder 
from a vial, liquid fo rmulation delivered by auto injector, liquid formulation delivered b y 
safet y syringe, in accordance with the randomization schedule generated b y Clinical 
Statistics, prior to the start of the study , using validated internal software. Randomization 
numbers will be allocated centrall y via interactive response technology (IRT).  The 
randomisation will be stratified by  body  weight (<70kg, 70- <80kg and ≥80kg) measured 
at day  -1. The site of injection will also be randomised 1:1:1 to the upper arm, abdomen 
or thi gh.
6.4. Blinding
This will be an open -label single dose stud y.
6.5. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
6.6. Preparation/Handling/Storage/A ccountability
Mepolizumab must be stored in a refrigerator or at a temperature of 2 -8C and protected 
from light. 
2016N275057_03 CONFIDENTIA L
204958
33Under normal conditions of handling and administration, investigational product is not 
expected to pose significant safet y risks to site staff. Take adequate precautions to avoid 
direct ey e or skin contact and the generation of aerosols or mists. Notify  the monitor of 
any unintentional occupational exposure. A Material Safet y Data Sheet (MSDS)
/equivalent document describing the occupational hazards of mepolizumab and 
recommended handling pre cautions will be provided to site staff if required by local laws 
or will otherwise be available from GSK upon request.
A description of the methods and materials required for mepolizumab will be detailed in 
the SRM.
Only  subjects enrolled in the study  may receive study  treatment and onl y authorized 
site staff may  supply  or administer study  treatment. All study  treatments must be 
stored in a secure environmentally  controlled and monitored (manual or automated) 
area in accordance with the labelled storage c onditions with access limited to the 
investigator and authorized site staff. 
The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y treatment accountability, reconciliation, and record 
maintenance (i.e., receipt, reconciliation and final disposition records).
Further guidance and information for final disposition of unused study  treatment are 
provided in the SRM. 
Mepolizumab ly ophile will be provided as a l yophilised drug product in sterile vial s for 
individual use and should be stored in a refrigerator at 2- 8°C with protection from light. 
The vial will be reconstituted with Sterile Water for Injection, just prior to use .  Each vial 
will contain 100 mg mepolizumab as a single 1.0 mL  injection (10 0 mg/mL).
Maintenance of a temperature log at the clinical dispensing sites (manual or automated) is 
required.
Mepolizumab liquid will be supplied in a single use safet y syringe and prefilled sy ringe 
contained within an autoinjector and both should be stored in a refrigerator at 2 -8°C with 
protection from light. Each injection device will contain 100 mg mepolizumab as a single 
1.0 mL  injection of the liquid formulation (100 mg/mL). Maintenance of a temperature 
log at the clinical dispensing sites (manual or automated) is required.
6.7. Training Session
Training of qualified site personnel in study  treatment handling and administration 
techniques at each stud y site will be provided by  GSK prior to the first subject 
administration at a given site. Further details of the training will be provided in the SRM.
6.8. Compliance with Study  Treatment A dministration
Subjects will receive study  treatment directl y from the investigator or designee, under 
medical supervision.  The date and time of each dose administered in the cl inic and site 
of administration (thigh, abdomen or upper arm) will be recorded in the source 
documents.  The study  treatment, dose and study  subject identification will be confirmed 
2016N275057_03 CONFIDENTIA L
204958
34at the time of dosing b y a member of the stud y site staff other than the p erson 
administering the stud y treatment.  
In the event of an acute severe reaction (e.g., anaphylaxis) following administration of 
mepolizumab, there are personnel/staff onsite at the treatment facility  who are 
appropriatel y trained in basic life support to manage the subject including administration 
of medications (e.g., epinephrine), and have access to a sy stem that can promptly  
transport the subject to another facility  for additional care if appropriate.
6.9. Treatment of Study  Treatment Overdose
The dose of mepolizumab considered to be an overdose has not been defined. There are 
no known antidotes and GSK does not recommend a specific treatment in the event of a 
suspected overdose. The investigator will use clinical judgment in treating the sy mptoms 
of a sus pected overdose.
6.10. Treatment after the End of the Study
Subjects will not receive any additional treatment from GSK after completion of the 
study  because onl y healthy subjects are eligible to participate in the stud y.
6.11. Lifest yle and/or Dietary  Restrictions
6.11.1. Caffeine, A lcohol, and Tobacco
During the dosing session, subjects will abstain from ingesting caffeine -or xanthine -
containing products (e.g., coffee, tea, cola drinks and chocolate) for 12 hours prior to 
the start of dosing until collection of the final ph armacokinetic and/or PDsample of 
the session and prior to all out -patient visits. 
During the dosing session, subjects will abstain from alcohol for 24 hours prior to the 
start of dosing until collection of the final pharmacokinetic and/or PDsample of th e 
session and prior to all out -patient visits. 
Use of tobacco products is not allowed from 6 months prior to screening until after 
the final follow -up visit.
6.11.2. Activity
Subjects will abstain from strenuous exercise for 48 hours prior to each blood collectio n 
for clinical laboratory  tests.  Subjects may  participate in light recreational activities 
during the stud y (e.g. read).
Subjects should abstain from any  activities likely  to result in any  significant decrease or 
increase in body  weight during the study  period (e.g. ‘crash’ dieting, bodybuilding).
2016N275057_03 CONFIDENTIA L
204958
356.12. Concomitant Medications and Non -Drug Therapies
6.12.1. Permitted Medications and Non -Drug Therapies
Concomitant medications are not allowed during this study  as outlined in Section 5.2
(exclusion criteria). 
Paracetamol (acetaminophen) 2g/day  as a mild analgesic is allowed throughout the 
study . Other concomitant medication may be considered on a case by  case basis by  the 
investigator in consultation with the Medical Monitor i f required.
6.12.2. Prohibited Medications and Non- Drug Therapies
Subjects must refrain from the use of prescription or non -prescription drugs, including 
vitamins, herbal and dietary  supplements (including St John’s Wort) within 7 day s (or 14 
days if the drug is a potential enzy me inducer) or 5 half -lives (whichever is longer) prior 
to the first dose of study medication until completion of the follow -up visit, unless in the 
opinion of the I nvestigator and GSK Medical Monitor the medication will not interfere 
with t he study  procedures or compromise subject safet y.
Recreational drug use is not allowed during the study .
7. STUDY A SSESSMENTS A ND PROCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence t o the study  design requirements, including those 
specified in the Time and Events Table (Section 7.1), are essential and required for stud y 
conduct.
This section lists the procedures and parameters of each plann ed study  assessment.  The 
exact timing of each assessment is listed in the Time and Events Table Section 7.1
The following points must be noted: 
If assessments are scheduled for the same nominal time, THEN theassessments 
should occur in the following order:
1. 12 -lead ECG
2.vital signs
3.blood draws.  
Note: The timing of the assessments should allow the blood draw to occur at the 
nominal time as stated in the SRM.
The timing and number of planned study  assessments, including safet y, 
pharmacokinetic, PD/biomarker assessments may  be altered during the course of 
the study  based on newly available data (e.g., to obtain data closer to the time of 
peak plasma concentrations) to ensure appropriate monitoring. 
2016N275057_03 CONFIDENTIA L
204958
36The change intiming or addition of time points for any planned study  
assessments must be documented in a Note to File which is approved by the 
relevant GSK study  team member and then archived in the study  sponsor and 
site study  files, but this will not constitute a pr otocol amendment. 
The IRB/IEC will be informed of any safet y issues that require alteration of the 
safet y monitoring scheme or amendment of the Informed Consent Form. 
No more than 500 mL of blood will be collected over the duration of the study , 
includin g any extra assessments that may  be required.
2016N275057_03 CONFIDENTIA L
204958
377.1. Time and Events Table
ProcedureScreening 
(up to 30 
days prior 
to Day 1)Treatment Period 1 [Days] Notes: 
Permitted Time 
windows will be 
defined in the GSK 
approved Windows 
Allowance 
Agreement used by 
each si teDay -11 2 3 4 5 6 7 8 910 15 22 29 43 57 85
(FUP/EW)
Informed consent X
Inclusion and 
exclusion criteriaX X
Demography X
Full physical exam 
including height1
and weight2X X
X1Height only at 
screening 
2Weight collected 
only at day -1
Medical history 
(includes 
substance usage) 
Including 
Cardiovascular 
medical 
history/risk factorsX
Alcohol test X XAlcohol measured in 
Serum
Drug ScreenX XSerum or Urine drug 
screen
Urine Cotinine test X X Tobacco 
2016N275057_03 CONFIDENTIA L
204958
38ProcedureScreening 
(up to 30 
days prior 
to Day 1)Treatment Period 1 [Days] Notes: 
Permitted Time 
windows will be 
defined in the GSK 
approved Windows 
Allowance 
Agreement used by 
each si teDay -11 2 3 4 5 6 7 8 910 15 22 29 43 57 85
(FUP/EW)
Past and current 
medical conditions  X
Pregnancy test X XX X All  pregnancy tests 
will be  performed in 
urine. 
Laborat ory 
assessments 
including 
haematology, 
chemistry and 
urinanalysisX X XXIncludes Liver 
chemistry
HIV, Hep B and 
Hep C screenXIf test otherwise 
performed within 3 
months prior to first 
dose of study 
treatment, testing at 
screening is not 
required
Immunogenicity X X3 X XX3Day 1 Predose. 
Including ADA and 
Nab
12-lead ECG X X X Day 1 –Predose
2016N275057_03 CONFIDENTIA L
204958
39ProcedureScreening 
(up to 30 
days prior 
to Day 1)Treatment Period 1 [Days] Notes: 
Permitted Time 
windows will be 
defined in the GSK 
approved Windows 
Allowance 
Agreement used by 
each si teDay -11 2 3 4 5 6 7 8 910 15 22 29 43 57 85
(FUP/EW)
Vital signs X X X4 X X X X X X XX4Day 1 –Predose
Parasite screening X55Only required in high 
risk countries or for 
subjects who have 
visited high risk 
countries in the past 
six months.  Sites 
should use local 
laboratories
Randomisation X
Study Treatment XComplete either the 
autoinject or or the 
safety syringe 
functionality 
assessment (see 
Section 7.4.4 ) when 
applicable
AE review X ========================================================================== Including local 
injection site 
reactions and 
systemic reactions
Collected from day -1 
to Day 85
2016N275057_03 CONFIDENTIA L
204958
40ProcedureScreening 
(up to 30 
days prior 
to Day 1)Treatment Period 1 [Days] Notes: 
Permitted Time 
windows will be 
defined in the GSK 
approved Windows 
Allowance 
Agreement used by 
each si teDay -11 2 3 4 5 6 7 8 910 15 22 29 43 57 85
(FUP/EW)
SAE review X X========================================================================== Including local 
injection site 
reactions and 
systemic reactions
Collected from 
screening to Day 85
Concomitant 
medication reviewX X========================================================================== Collected from 
screening to Day 85
Blood Samples for 
PK X6 X X X X X X X X X X X X XX X6Day 1 –Predose, 2h 
& 8h Postdose
Blood sample s for 
PD (blood 
eosinophils)X7 X X
X XX X7Day 1 –Predose
Autoinjector and 
safety syringe 
user/device error 
assessmentX HCP reported. See 
Section 7.4.4 . 
Follow up (FUP) X
2016N275057_03 CONFIDENTIA L
204958
417.2. Screening and Critical Baseline A ssessments
A subject number will be assigned at the time the informed consent form (ICF) is signed.  
During the screening Visit, study  designated personnel must provide informed consent to 
study  participants .
Once the informed consent document has been signed, screening assessments can be 
conducted. The following demographic parameters will be captured: year of birth, sex, 
race and ethnicit y. From the screening visit onwards concomitant medications and SAEs 
(considered as related to study  participation) must be reported.
7.2.1. Critical procedures performed at Screening
Medical history  including smoking status, current treatment 
Cardiovascular medical history /risk factors (as detailed in the eDC s ystem). This 
assess ment must include a review of the subject responses to the cardiovascular 
assessment questions and height, weight, blood pressure, smoking history , medical 
conditions, and family  history  of premature cardiovascular disease.
Physical exam 
Vital signs
12-lead ECG
Laboratory  tests. This should include:
Chemistry
Haematology  with differential count
Urinaly sis
Pregnancy  test (serum) 
FSH 
Parasitic screening (only in countries with a high-risk or in subjects who have 
visited a high -risk country )
HIV, Hep B, Hep C screen
Blood for Immunogenicity 
Review of Inclusion/Exclusion criteria
Review of SAEs
2016N275057_03 CONFIDENTIA L
204958
427.2.2. Critical procedures performed at first treatment visit
Vital signs 
Blood for PK assessment
Blood for PD assessment (pre -dose sample)
Blood for Immunogenicity (pre -dose sample)
12 lead ECG
Study  treatment
Device functionality  questions
Review concomitant medications, AEs, SAEs
7.3. Safet y
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Section 7.1).  
7.3.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 3 . 
The following adverse events of special interest will have additional information (i.e. 
corresponding s ymptoms) collected via AE and SAE pages in the eDC:
Local injection site reactions
Systemic reactions 
In addition, the information whether an event met the diagnostic criteria for anaph ylaxis 
as outlined by  the Second Sy mposium on Anaphylaxis [Sampson, 2006] and in Appendix 
6will be collected on the AE and SAE eDC pages.
The investigator and their designees are responsible for detecting, documenting and 
reporting eve nts that meet the definition of an AE or SAE. 
7.3.1.1. Time period and Frequency  for collecting A E and SA E information
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, invasive tests, or change in existing therap y) or relate d to a GSK product 
will be recorded from the time a subject consents to participate in the stud y up to and 
including an y follow -up contact. 
AEs will be collected from the start of Study  Treatment until the follow -up contact 
on Day  85 (see Section 7.3.1.3 ), at the timepoints specified in the Time and Events 
Table (Section 7.1).
Medical occurrences that begin prior to the start of study treatment but after 
obtaining inf ormed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the eDC.
2016N275057_03 CONFIDENTIA L
204958
43All SAEs will be recorded and reported to GSK within 24 hours, as indicated in the 
Time and Events T able Section 7.1.
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, including a death, at an y 
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the investigator 
must promptly  notify  GSK.
NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to GS K are provided in 
Appendix 3 .
7.3.1.2. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non- leading verbal questioning of the subject is the preferred meth od to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?” 
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?” 
7.3.1.3. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs, and non -serious AEs of special interest 
(as defined in Section 4.6.1 ) will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up 
(as defined in Section 5.4). Further information on follow -up procedures is given in 
Appendix 3 .
2016N275057_03 CONFIDENTIA L
204958
447.3.1.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  the investigator to GSK of SAEs related to study treatment (even 
for non -interventional post -marketing studies) is essential so that legal obligations and 
ethical responsibilities towards the safet y of subjects and the safety of a product under 
clinical investigation are met. 
GSK has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  GSK will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and GSK policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from GSK will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
7.3.2. Pregnancy
Details of all pregnancies in female subjects will be collected after the start of dosing 
and until 16 weeks after last dose. 
 If a pregnancy is reported then the investigator should inform GSK within 2 weeks 
of learning of the pregnancy  and should follow the procedures outlined in Appendix 
5.
7.4. Medical Device Incidents (Including Malfunctions)
GSK medical devices are being provided for use in this study .  In order to fulfil 
regulatory  reporti ng obligations worldwide the investigator is responsible for the 
detection and documentation of events meeting the definitions of incident or malfunction 
that occur during the study with such devices. 
The definition of a Medical Device Incident can be fou nd in Appendix 4 .
NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Section 7.3.1 and Appendix 3 of the Protocol. 
7.4.1. Time Period for Detecting Medical Device Incidents
Medical device incidents or malfunctions of the device that result in an incident will 
be detected, documented and reported during all periods of the stud y in which the 
GSK medi cal devices are available for use. 
If the investigator learns of an y incident at an y time after a subject has been 
discharged from the study, and such incident is reasonably related to a GSK medical 
device provided for the study , the investigator will promptly  notify  GSK.
2016N275057_03 CONFIDENTIA L
204958
45NOTE: The method of documenting Medical Device Incidents is provided in Appendix 
4.
7.4.2. Follow -up of Medical Device Incidents
All medical device incidents involving an AE, will be followed until resolutio n of 
the event, until the condition stabilizes, until the condition is otherwise explained, or 
until the subject is lost to follow -up (as defined in Section 5.5). The investigator is 
responsible for ensuring tha t follow -up includes any  supplemental investigations as 
may be indicated to elucidate as completel y as practical the nature and/or causality  of 
the incident.
New or updated information will be recorded on the originally  completed form with 
all changes sign ed and dated by  the investigator.
7.4.3. Prompt Reporting of Medical Device Incidents to GSK
Medical device incidents will be reported to GSK within 24 hours once the 
investigator determines that the event meets the protocol definition of a medical 
device inciden t.
Facsimile transmission of the "Medical Device Incident Report Form" is the 
preferred method to transmit this information to the Medical Monitor. The same 
individual will be the contact for receipt of medical device reports and SAEs.
In the absence of fa csimile equipment, notification by  telephone is acceptable for 
incidents, with a cop y of the "Medical Device Incident Report Form" sent by 
overnight mail. 
7.4.4. Autoinjector and safety syringe functionality assessment
During administration of the autoinjector a nd safety  syringe the HCP will be asked to 
inspect the medical device and complete the inspection questions in Appendix 7 and 
Appendix 9 respectivel y.
If there is an error with the medical device then refer to the Autoinjector or safet y syringe 
Error / Failure Reporting Form in Appendix 8 or Appendix 10 respectively . 
7.4.5. Returning defective Medical Devices to GSK
All defective devices will be returned to GSK
Please refer to the SRM for all details 
7.4.6. Regulatory  Reporting Requirements for Medical Device Incidents
The investigator will promptly  report all incidents occurring with any  GSK medical 
device provided for use in the study  in order for GSK to fulfil the legal responsibility  
to notify  appropriate regulatory  bodies and other entities about certain safety  
information relating to medical devices being used in clinical studies.
2016N275057_03 CONFIDENTIA L
204958
46The investigator, or responsible p erson according to local requirements (e.g., the 
head of the medical institution in Japan), will comply  with the applicable local 
regulatory  requirements relating to the reporting of incidents to the I RB/IEC.
7.5. Physical Exams
Consider further specification (e.g. for height and weight measurements, the subject is 
allowed to wear indoor, day time clothing with no shoes) if appropriate to the study .
A complete ph ysical examination will include, at a minimum, assessment of the 
Cardiovascular, Respiratory , Gastroin testinal and Neurological s ystems. Height and 
weight will also be measured and recorded.
7.5.1. Vital Signs
Vital signs will be measured in supine position after 5 minutes rest and will include 
temperature, systolic and diastolic blood pressure, pulse rate and r espiratory  rate. 
7.5.2. Electrocardiogram (ECG)
Single 12-lead ECGs will be obtained at each timepoint during the stud y using an 
ECG machine that automatically  calculates the heart rate and measures PR, QRS, 
QT, and QTc intervals.  
If a routine single ECG demon strates a prolonged QT interval, obtain two more 
ECGs over a brief period, and then use the averaged QTc values of the three ECGs. 
Refer to Section 5.4.3 for additional QTc readings that may  be necessary .
ECG me asurements will be made after the subject has rested in the supine position 
for 5 minutes.  The ECG should be obtained before the vital signs assessments and 
followed b y other stud y procedures. 
7.5.3. Clinical Safety  Laboratory  Assessments
All protocol required laboratory  assessments, as defined in Section 7.1, must be 
conducted in accordance with the L aboratory  Manual, and Protocol Time and Events 
Schedule. Laboratory  requisition forms must be completed and samples must be clearl y 
labelled with the subject number, protocol number, site/centre number, and visit date.
Details for the preparation and shipment of samples will be provided b y the laboratory 
and are detailed in the SRM. Reference ranges for all safet y parameters will be provided 
to the site by  the laboratory  responsible for the assessments.
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  the investigator (e.g., SAE or AE or dose 
modification) the results must be recorded in the eDC.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.
2016N275057_03 CONFIDENTIA L
204958
47Haematology , clinical chemistry , urinal ysis and additional parameters to be tested are 
listed in Table 2.
Table 2 Protocol Required Safety  Laboratory  Assessments
Laboratory  
AssessmentsParameters
Haematology Platelet Count RBC Indices: WBC count with Differential:
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline phosphatase Albumin
CK
Routine 
Urinaly sisSpecific gravit y
pH, glucose, protein, blood and ketones b y dipstick
Microscopic examination (if blood or protein is abnormal) 
Urine microscopic examination : RBC, WBC, Epithelial cells, Casts 
(hyaline, granular, cellular)
Other 
Screening 
TestsHIV
Hepatitis B (HBsAg)
Hepatitis C (Hep C antibody )
FSH and estradiol (as needed in women of non -child bearing 
potential only )
Alcohol and drug screen (to include at minimum: cot inine, 
amphetamines, barbiturates, cocaine, opiates, cannabinoids and 
benzodiazepines)
Pregnancy -  All  tests will be performed in urine. 
Immunogenicit y –Nab, ADA
Parasitic screening – for subjects who have travelled to countries 
with a high-risk 
NOTES :
1.Details of Required Actions and Follow -Up Assessments after liver event are 
given in Section 5.4.2 and Appendix 2 .
All laboratory  tests with values that are considered clinically  significantl y abnormal 
during participation in the study  should be repeated until the values return to normal or 
baseline.  If such values do not return to normal within a period judged reasonable b y the 
investigator, the etiology should be iden tified and the sponsor notified.
2016N275057_03 CONFIDENTIA L
204958
487.6. Pharmacokinetics
7.6.1. Blood Sample Collection
Blood samples for determination of mepolizumab plasma concentration will be collected 
at the time points indicated in Section 7.1, Time a nd Events Table.  The actual date and 
time of each blood sample collection will be recorded.  The timing of PK samples may  be 
altered and/or PK samples may  be obtained at additional time points to ensure thorough 
PK monitoring.   Further details will be sp ecified in the Study  Reference Manual (SRM).
7.6.2. Sample A nalysis
Plasma analy sis will be performed under the control of PTS, GSK , the details of which 
will be included in the Study  Reference Manual (SRM). Concentrations of mepolizumab 
will be determined in pl asma samples using the currentl y approved bioanalytical 
methodology . Raw data will be archived at the bioanal ytical site (detailed in the SRM).
Once the plasma has been anal yzed for mepolizumab any  remaining plasma may  be 
analyzed for other compound -related material and the results reported under a separate 
PTS, GSK protocol.
7.7. Pharmacody namic Markers
Blood eosinophil counts will be recorded at the visits specified in the Time and Events 
Schedule (Section 7.1).  
7.8. Immunogenicity
Blood samples will be collected for the determination of anti- mepolizumab antibodies, 
prior to dosing and as detailed in the Time and Events Schedule (Section 7.1)
Details for sample collection and processing may  be found in the SRM.
8. DATA MANAG EMENT
For this study  subject data will be entered into a GSK approved database and 
combined with data provided from other sources in a validated data s ystem. The data 
will be transmitted electronically  to GSK .  
Management of clinical data will be performed in accordance with approved GSK 
standards and data cleaning procedures to ensure the integrity of the data, e.g., 
removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary  for Regulatory  Activities) and an internal validated medication 
dictionary , GSKDrug.  
Subject initials and full date of birth will not be collected or transmitted to GSK 
according to GSK policy .
2016N275057_03 CONFIDENTIA L
204958
499. STATIST ICAL CONSIDERA TIONS AND DA TA 
ANALYSES
9.1. Hypotheses
This study  is designed to evaluate mepolizumab PK comparabilit y following a single SC 
administration, i.e. the relative bioavailability , between 
The liquid drug product from the autoinjector (test) and the reconstituted 
lyophilised drug product from the vial (reference)
The liquid drug product from the safet y syringe (test) and the reconstituted 
lyophilised drug product from the vial (reference)
For AUC (0-t), AUC (0-∞)and Cmax, point estimates and corresponding two- sided 90% 
confidence intervals (CI) will be constructed for the ratio of the geometric mean of each 
test treatment to the geometric mean of the reference treatment, μ(test)/μ(reference). No 
formal h ypothesis will be tested. However, interpretation of the comparability  of the 
autoinjector and safet y syringe with the reconstituted ly ophilised drug product will be 
guided b y a two -sided 90% CI for μ(test)/μ(reference) in the range (0.80, 1.25) for 
AUC (0-t),AUC (0-∞)and Cmax.
9.2. Sample Size Considerations
The primary  objective of this study  is to evaluate the PK comparability  of the liquid drug 
product administered b y both the autoinjector and safet y syringe with the l yophilised 
drug product when reconstituted f rom the vial. The sample size for this study  is based on 
the number of subjects needed to demonstrate a two-sided 90% CI for 
μ(test)/μ(reference) within the guide range of (0.80, 1.25) for AUC (0-∞), AUC (0-t) and 
Cmax.
Variability  estimates for AUC (0-∞), AU C(0-τ) and Cmax for mepolizumab were considered 
from three studies; SB -240563/017, SB -240563/018 and MEA114092. Only  data from 
treatment groups with SC administration of mepolizumab in the upper arm, abdomen or 
thigh, for doses of 125mg and 250mg across the 3 studies was considered. 
For AUC, estimates for the between subject standard deviation on the log escale, after 
adjusting for bod y weight, ranged from 0.18 to 0.27, with a mean (weighted by  degrees 
of freedom) estimate of 0.222. For Cmax, estimates for the between subject standard 
deviation on the log escale, after adjusting for body  weight, ranged from 0.20 to 0.32, 
with a mean (weighted by  degrees of freedom) estimate of 0.252.
The joint power to demonstrate an observed 90% CI  within the guide range ( 0.80, 1.25) 
for AUC (0-t), AUC (0-∞)and Cmax for both the autoinjector and safet y syringe has been 
estimated using simulation. Assuming standard deviations on the log escale of 0.222 for 
AUC (0-t), AUC (0-∞)and 0.252 for Cmax (i.e. the mean estimates given above), a true 
difference between the formulations of 5% and a within subject correlation between AUC 
and Cmax of 0.8, the estimated joint power with 72 subjects per treatment group is 98%. 
Assuming standard deviations on the log escale of 0.27 for AUC (0-t), AUC (0-∞)and 0.32 
2016N275057_03 CONFIDENTIA L
204958
50for Cmax (i.e. the highest estimates given above), and with all other assumptions as 
above, the estimated joint power with 72 subjects per treatment group is 89%.
To allow for a dropout rate of up to 10%, approximately  243 subjects (81 per t reatment 
group) will be enrolled in this study .
No sample size re -estimation will be performed.
9.3. Data Analysis Considerations
Final anal ysis will be performed after the completion of the study  and final data base 
freeze. Complete details of the planned anal ysis will be documented in the Reporting and 
Analy sis Plan (RAP).
9.3.1. Analysis Populations
9.3.1.1. All Treated Subjects Population
The ‘All Treated Subjects’ population will comprise all subjects who receive 
mepolizumab. This population will be used for all safet y and tolerability , study  
population and exploratory  anal yses.
9.3.1.2. Pharmacokinetic Population
The pharmacokinetic population will comprise all subjects in the ‘All Treated Subjects’ 
population who have at least one PK sample obtained and analy sed. This population w ill 
be used for all pharmacokinetic anal yses, including the primary  analy sis.
9.3.2. Interim A nalysis
No interim anal yses are planned.
9.4. Key Elements of A nalysis Plan
9.4.1. Raw Plasma Concentrations
Blood sampling time will be related to the start of dosing. Linear and s emi-logarithmic 
individual plasma concentration- time profiles and mean and median profiles will be 
plotted for each treatment. Plasma concentrations of mepolizumab will be listed and 
summarised by treatment group and within each treatment group by  weight c ategory  
(<70kg, 70- <80kg and ≥80kg) and b y injection site; and nominal time.
9.4.2. Derived Plasma Pharmacokinetic Parameters
Pharmacokinetic anal ysis will be the responsibility of the Clinical Pharmacology
Modeling and Simulation Department, QSci, GSK. Plasma concentrat ion time data for
mepolizumab will be analy zed by  non-compartmental methods according to 
GlaxoSmithKline guidance document, GUI_00000051487 and using WinNonlin.
Calculations will be based on the actual sampling times recorded du ring the study .
From the plasma concentration time data, the following pharmacokinetic parameters will
2016N275057_03 CONFIDENTIA L
204958
51be determined, as data permit, for each treatment and for each subject:
• maximum observed plasma concentration (Cmax)
• time to Cmax (tmax)
• area unde r the plasma concentration time curve [AUC(0 -t), AUC(0 -week4) and AUC
(0-∞)]
• %AUCextrapolated
• Last time point where the concentration is above the limit of quantification (tlast)
• Apparent clearance (CL/F)
• Apparent volume of distribution (Vd/F)
• terminal phase elimination rate constant (λz)
• the number of points used to determine λz
• the terminal phase half -life (t1/2).
Pharmacokinetic data will be presented in graphical and/or tabular form and will be listed 
and summarized descriptively  by treat ment group, and within each treatment group b y 
weight category  (<70kg, 70- <80kg and ≥80kg) and by  injection site.  
All pharmacokinetic data will be stored in the Archives, GlaxoSmithKline 
Pharmaceuticals, R&D.
Statistical analy ses of the pharmacokinetic p arameter data will be the responsibility  of
Clinical Statistics, GlaxoSmithKline.
9.5. Primary  Analyses
The primary  anal ysis will compare AUC (0-t), AUC (0-∞)and Cmax for each test treatment 
(liquid formulation from the autoinjector or safet y syringe) to the ref erence (reconstituted 
lyophilised powder from the vial). The anal ysis for each treatment comparison will be 
conducted excluding the data from the test treatment that is not relevant for that 
comparison. The parameters AUC (0-t), AUC (0-∞)and Cmax will be log etransformed and 
analysed separatel y using a fixed effects model, including treatment group and injection 
site (upper arm, abdomen, thigh) as categorical variables and baseline weight as a 
continuous covariate fitted on the log e scale. Point estimates an d associated two -sided 
90% CIswill be constructed for the differences between the test and reference treatments 
on the log escale; these will be back -transformed to provide point estimates and two -sided 
90% CI s for the ratio of each of the test treatments to the reference treatment on the 
original scale.
9.6. Secondary  Analyses
Safety  data will be presented in tabular and/or graphical format and summarised 
descriptivel y according to GSK’s Integrated Data Standards L ibrary  (IDSL) standards. 
AEs will be coded usi ng the MedDRA coding dictionary  and summarized by  preferred 
term. Separate summaries will be provided for all AEs, I P-related AEs, SAEs, events of 
special interest (including s ystemic reactions and local injection site reactions). 
2016N275057_03 CONFIDENTIA L
204958
52All laboratory  parameter s for clinical chemistry  and haematology  will be summarized 
and tabulated.
Each ECG parameter at every  assessed time point will be summarized. Summary  
statistics of QT interval corrected for heart rate according to Frederica’s formula (QTcF) 
and QT interva l corrected for heart rate according to Bazett’s formula (QTcB) as well as 
change from baseline values will be presented b y time point.
Summary  statistics of pulse rate and sy stolic and diastolic blood pressure will be 
presented by time point.
Immunogenici ty will be summarized using appropriate descriptive statistics.
9.6.1. Exploratory  Analyses
Ratio to baseline in blood eosinophil count will be log transformed and compared 
between treatments using a mixed model repeated measures anal ysis, adjusting for the 
covar iates of baseline blood eosinophil count (log scale) and baseline weight (log scale). 
Time point and injection site (upper arm, abdomen, thigh) will be fitted as a categorical 
variables with the effect of treatment group and baseline blood eosinophil count varying 
at each timepoint (i.e. timepoint- by-baseline and timepoint- by-treatment interactions will 
be included in the model).
User and device errors will be summarized using appropriate descriptive statistics.
10. STUDY GOVERNANCE CON SIDERATIONS
10.1. Posting of In formation on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, GSK will obtain favourable opinion/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requiremen ts.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with GSK policy .
The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guidi ng principles of the 1996  
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opinion/approval of the study  protocol and 
amendments as applicable
2016N275057_03 CONFIDENTIA L
204958
53Obtaining signed informed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol deviations 
to IRB/IEC)
GSK will provide full details of the above procedures, either verball y, in writing, or 
both.
Signed informed consent must be obtained for each subject prior to part icipation in 
the study
The IEC/I RB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.  
Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where required b yregulatory  authorities.  I n this situation, written 
approval of the clinical protocol should state that approval of optional assessments is 
being deferred and the study , with the exception of the optional assessments, can be 
initiated.
10.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and GSK procedures, 
GSK monitors will contact the site prior to the start of the study  to review with the 
site staff the protocol, study  requirements, and their responsibilities to sa tisfy 
regulatory , ethical, and GSK requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the eDC sy stem 
will serve as the source document.
GSK will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  other 
study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents.
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, GSK 
may conduct a quality  assurance assessment and/or audit of the site records, and the 
regulatory  agencies may  conduct a regulatory  inspection at any  time during or after 
completion of the study . 
2016N275057_03 CONFIDENTIA L
204958
54In the event of an assessment, a udit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss the 
conduct of the stud y, an y findings/relevant issues and to implement any  corrective 
and/or preventative actions to address any findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the GSK monitor will 
conduct site closure activ ities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and GSK Standard Operating 
Procedures.
GSK reserves the right to temporaril y suspend or prematurel y discontinue this study  
at an y time for r easons including, but not limited to, safet y or ethical issues or severe 
non-compliance. For multicenter studies, this can occur at one or more or at all sites.  
If GSK determines such action is needed, GSK will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where 
applicable).  When feasible, GSK will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the stud y is su spended or prematurely  discontinued for safet y reasons, GSK will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . GSK will also promptly  
inform the relevant regulatory  autho rities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study, the investigator or the head of the medical institution 
(where applicable) must maintain all site study  records (except for those required b y 
local regulations to be maintained elsewhere), in a safe and secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a GSK audit or regulatory  inspection) and must be available for review in 
conjunctio n with assessment of the facility , supporting s ystems, and relevant site 
staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of these 
records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval standards, including 
2016N275057_03 CONFIDENTIA L
204958
55re-generating a hard copy , if required.  Furthermore, the investigator must ensure 
there is an acceptable back- up of these reproductions and that an acceptable quality  
control process exists for making these reproductions.
GSK will inform the investigator o f the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by an y 
institutional requirements or local laws or regulations, GSK standards/procedures, 
and/or institutional requirements.  
The investigator must notify  GSK of any  changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility  or transfer of ownership 
of the records in the event the investigator is no longer associated with the site.
10.7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the com plete study  results at a GSK site or other mutually -
agreeable location.
GSK will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
GSK will provide the investigator with the randomization codes for their site only  after 
completion of the full statistical analy sis.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publicatio n will be in accordance with GSK Policy .
A manuscript will be progressed for publication in the scientific literature if the results 
provide important scientific or medical knowledge.
2016N275057_03 CONFIDENTIA L
204958
5611. REFERENCES
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey  SW et al. Oral 
Glucocorticoid -Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Engl J Med 
2014 September 8;371(13):1189-97.
Chioato A (2013).  Canakimumab bioequivalence: sy ringe vs dry  powder.  Clin Drug 
Investig. 33; 801-808.
CHMP, 2005 - EMA -Guideline on Adjuvants in Vaccines for Human Use, 
(CHMP/VEG/134716/2004), January  2005.
Cole L A, Khanlian SA, Sutton JM, Davies S, Rayburn WF. Accuracy  of home pregnancy  
tests at the time of missed menses. Am J Ob Gy n 2004(190):100-5.
EMA/CHMP/I CH/449035/2009: General principles to address virus and vector shedding. 
http://www.ema.europa.eu/docs/en_GB/document_library /Scientific_guideline/2009/09/
WC500002680.pdf Accessed 28 Nov 2014.
EMEA/CHMP/GTWP/125459/2006: Guideline on the Nonclinical Studies Required 
Before First Clinical Use of Gene Therapy  Medicinal Products [2008]
European Medicines Agency  / GUIDELINE ON THE INVESTIGATION OF 
BIOEQUIVALENCE/ 
ema.europa.eu/docs/en_GB/document_library /Scientific_guideline/2010/01/
FDA CBER Guidance for industry , “Conside rations for Developmental Toxicity  Studies 
for Preventive and Therapeutic Vaccines for Infectious Disease Indications. U.S. FDA; 
Feb. 2006. 
FDA Medical Devices Safet y Alerts and Notices, “Blood human chorionic gonadotropin 
(hCG) assay s:What laboratorians should know about false -positive results”, 
http://www.fda.gov/MedicalDevices/Safet y/AlertsandNotices/TipsandArticlesonDeviceS
afety/ucm109390.htm, accessed 17 Nov 2014.
GlaxoSmithKline Document Number (2016N290279_00). Investigator’s Brochure for 
SB-240563. 01- AUG -2016.
GlaxoSmithKline Document Number (CM2003/00010/10). I nvestigator’s Brochure for 
SB-240563. 03- DEC -2015.
GlaxoSmithKline guidance document, GUI_00000051487. Non- Compartmental Anal ysis 
of Pharmacokinetic. 29 -Oct-2014.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, editors. 
Contraceptive Technology . 19th edition. New York: Ardent Media, 2007(b): 28.
2016N275057_03 CONFIDENTIA L
204958
57Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, et.al., editors. 
Contraceptive Technology . 20thedition. Atlanta, Georgia: Ardent Media, Inc., 2011: 50.
Table 3-2.
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Use. ICH Harmonized Tripartite Guideline. Detection of 
Toxicity  to Reproduction for Medicinal Products & Toxicity  to Male Fertility .Parent 
Guideline dated 24 June 1993 (Addendum dated 9 November 2000 incorporated in 
November 2005. ICH S5 (R2)
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Use.   ICH Harmonized Tripartite Guideline. Nonclinical 
Evaluation for Anticancer Pharmaceuticals. ICH S9. 2009.
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Us e.ICH Harmonized Tripartite Guideline. Nonclinical 
Safety  Studies for the Conduct of Human Clinical Trials and Marketing Authorization for 
Pharmaceuticals. ICH M3 (R2). 2009.
International Conference on Harmonization of Technical Requirements for Regist ration 
of Pharmaceuticals For Human Use. ICH Harmonized Tripartite Guideline. Preclinical 
Safety  Evaluation of Biotechnology -Derived Pharmaceuticals. ICH S6 and Addendum 
ICH S6 (R1). 2011.
Kronenberg HM , Melmed S, Polonsky  KS, Larsen PR, editors. Willia ms Textbook of 
Endocrinology , 11th edition. Philadelphia: Saunders, 2008.
Ortega HG, L iu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. 
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med 
2014 September 8;371(13):1198-207.
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma 
(DREAM): a multicentre, double- blind, placebo -controlled trial. Lancet 2012;380:651 –
59.
Pourvasei R (2013).  Denosumab biocomparability. AAPS 15(1); 70 -77
Riviere GJ ( 2011).  Omalizumab bioequivalence injection solution vs dry  powder. J 
Bioequiv Avalailab. 3(6) 144-150.
Sampson HA, Munoz- Furlong A, Campbell RL , et. Al. Second sy mposium on the 
definition and management of anaph ylaxis: summary  report—Second National I nstitute 
of Allergy  and Infectious Disease/Food Allergy  and Anaphy laxis Network sy mposium. J 
Allergy  Clin Immunol 2006;117:391 -397.
Strauss JF, Barbieri RL, editors. Yen and Jaffe’s Reproductive Endocrinology . 5th 
edition, Philadelphia, Elsevier/Saunders, 200 4.
2016N275057_03 CONFIDENTIA L
204958
58U.S. Dept of Health and Human Services, FDA, Center For Biologics Evaluation and 
Research: Guidance for Human Somatic Cell Therap y and Gene Therap y [1998]
WHO , 2013 - WHO - Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants 
and Adjuvanted Vac cines, 2013
World Health Organization. WHO/CONRAD Technical Consultation on Nonox ynol-9.
World Health Organization; Department of Reproductive Health and Research; Geneva; 
9-10 October 2001. Summary  Report. 2001. WHO/RHR/03.8.
Zenhua X (2015) Golimum ab autoinjector PK bridging.  Clinical Therapeutics 37(2); 
427-438.
2016N275057_03 CONFIDENTIA L
204958
5912. APPENDICES
12.1. Appendix 1 –Abbreviations and Trademarks
Abbrev iations
ACQ -5 Asthma Control Questionnaire
ADA Anti Drug Antibody
AE Adverse Event
AUC Area Under the Concentration- Time Cur ve
AUC(0 -week4) Area Under the Concentration- Time Curve from Time Zero 
(pre-dose) to Week 4
AUC(0 -t) Area Under the Concentration- Time Curve from Time Zero 
(pre-dose) to Last Time of Quantifiable Concentration
AUC(0 -∞) Area Under the Concentration- Time Curve from Time Zero 
Extrapolated to I nfinite Time
%AUCex Percentage of AUC(0 -∞) Obtained by  Extrapolation
AE Adverse Event
BMI Body Mass Index
CI Confidence Interval
CL/F Apparent Clearance Following Subcuta neous Dosing
Cmax Maximum Observed Concentration
CONSORT Consolidated Standards of Reporting Trials
COPD Chronic Obstructive Pulmonary  Disease
eDC Electronic data capture
EGPA Eosinophilic granulomatosis with poly angiitis
EOE Eosinophilic esophagitis
ECG Electrocardiogram
FEV1 Forced Expiratory  volume in 1 second
FRP Females of Reproductive potential
GSK GlaxoSmithKline
HBsAg Hepatitis B surface antigen
HCP Healthcare Provider
hCG Human chorionic gonadotrophin
HES Hypereosinophilic s yndrome
IB Investigator’s Brochure
IDSL Integrated Data Standards L ibrary
IL Interleukin
IV Intravenous
λz Terminal Phase Elimination Rate Constant
Nab Neutralising antibody
OCS Oral corticosteroids
PK Pharmacokinetic
PD Pharmacod ynamic
SAE Serious Adverse Event 
SC Subcutaneous
2016N275057_03 CONFIDENTIA L
204958
60SGRQ St George’s Respiratory  Questionnaire
SRM Study  reference manual
tlast Time of Last Observed Concentration
tmax Time to Cmax
t½ Terminal Phase Half -life
Vd/F Apparent Volume of Distribution Following Subcutaneous 
Dosing
WCBP Women of child bearing potential
WFI Water For Injection
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
NUCALA ™ WinNonlin
2016N275057_03 CONFIDENTIA L
204958
6112.2. Appendix 2 -Liver Safety  Required A ctions and Follow up 
Assessments
Liver chemistry  stopping criteria for healthy volunteers and required follow 
up assessments
Liver chemistry  stopping criteria have been designed to assure subject safety  and to 
evaluate liver event etiology  (in alignment with the FDA premarketing clinical liver 
safet y guidance).
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Since this is a single dose study  liver chemistry stopping criteria do not apply . However, 
in case of liver event following the single dose of study  treatment (defined as liver 
stopping event in table below) all required follow up assessments must be completed.
Liver chemistry  stopping criteria and requi red follow up assessments
Liver Chemistry Stopping Criteria – Liver Stopping Event
ALT-absoluteALT≥3xULN
If  ALT ≥3xULN  AND bilirubin1,22xULN (>35% direct bilirubin) or  INR>1.5, 
Report as an SAE.
See additional Actions and Follow Up Assessments li sted below
Required Actions and Follow up Assessments following Liver Stopping Event
Actions Follow Up Assessments
Report the event to GSK within 24 hours
Complete the liver event eDC, and complete an 
SAE data collection tool if the event also meets 
thecriteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries 
resolve, stabilise, or return to within baseline 
(see MONITORING below)
MONITORING:
If ALT ≥3xULN AND bilirubin 2xULN  or INR 
>1.5
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform liver 
event follow up assessments within  24 hrsViral hepatitis serology3
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total bilirubin 2xULN
Obtain complete blood count with differential to 
assess eosinophilia. Note: The mechanism of 
action of mepolizumab leads to lowering of 
eosinophils. 
Record the appearance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, on 
the AE report form
Record use of concomitant medications on the 
concomitant medications report form including 
acetaminophen, herbal remedies, other over 
the counter medications.
2016N275057_03 CONFIDENTIA L
204958
62Liver Chemistry Stopping Criteria – Liver Stopping Event
Monitor subjects twice weekly until liver 
chemistries resolve, stabili se or return to within 
baseline
A specialist or hepatology consultation is 
recommended
If ALT ≥3xULN AND bilirubin < 2xULN  and INR 
≤1.5:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform liver 
event follow up assessme nts within 24-72 hrs
Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baselineRecord alcohol use on the liver event alcohol 
intake case report form
If ALT ≥3xULN A ND bilirubin 2xULN  or INR 
>1.5:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney microsomal 
antibodies, and quantitative total 
immunoglobulin G (IgG or gamma globulins).
Serum acetaminophen adduct HPLC assay 
(quantifies poten tial acetaminophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [ James , 2009]. NOTE: not 
required in China .
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) and 
/or liver biopsy to evaluate liver disease; 
complete Liver Imaging and/or Liver Biopsy 
eDC forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately a vailable, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin ele vations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured, which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (Ig M); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA , et.al..
Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
2016N275057_03 CONFIDENTIA L
204958
6312.3. Appendix 3 -Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Re porting of A dverse Events
Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meet ingAE definition include:
Any abnormal laboratory test results (haematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae).
"Lack of effic acy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfil the definition 
of an AE or SAE.
The signs and sy mptoms and/or clinical sequelae resulting from lack of efficacy  will 
be reported if they  fulfil the definition of an AE or SAE.  Also, "lack of efficacy " or 
"failure of expected pharmacological action" also constitutes an AE or SAE.
2016N275057_03 CONFIDENTIA L
204958
64Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for t he subject’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
Medical or surgical procedure (e.g., endoscop y, appe ndectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/sy mptoms o f the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as an y untoward medical occurrence that, at an y 
dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires hospitalization or prolongation of existing ho spitalization
NOTE:
In general, hospitalization signifies that the subject has been detained (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for 
observation and/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospitalization are 
AEs.  If a complication prolongs hospitalization or fulfills any other serious criteria, 
the event is serious.  When in doubt as to whether “hospitalization” occurre d or was 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE.
2016N275057_03 CONFIDENTIA L
204958
65d.Results in disability /incapacity
NOTE:
The term disability  means a subst antial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
and accidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomal y/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding wheth er reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may  jeopardize 
the subject or may  require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition.  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or
convulsions that do not result in hospitalization, or development of drug dependency  
or drug abuse
g.Is associated with liver injury  andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported a s an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
Refer to Appendix 2 for the required liver chemistry  follow -up instructions
2016N275057_03 CONFIDENTIA L
204958
66Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospital progress notes, laborato ry, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the eDC
It is notacceptable for the investigator to send photocopies of the subject’s medical 
records to GSK in lieu of c ompletion of the GSK, AE/SAE eDC page.
There may  be instances when copies of medical records for certain cases are 
requested b y GSK.  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical records prior to 
submission of to GSK.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the indiv idual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accorda nce with standard scoring and statistical procedures detailed by  
the scale’s developer.
The use of a single question from a multidimensional health survey  to designate a 
cause -effect relationship to an AE is inappropriate.
Evaluating AEs and SA Es
Assessment of Intensit y
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  the subject, causing minimal discomfort
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be co nfused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE.
2016N275057_03 CONFIDENTIA L
204958
67Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors , and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her as sessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to GSK.  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to GSK.
The investigator may  change his/her opinion of causa lity in light of follow -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated t o perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  GSK to 
elucidate as fully  as possible the nature and/or causality  of the AE or SAE.
The investigator is obligated to assist.  This m ay include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide GSK with a copy  of any  post -mortem findings, 
including histopathology .
New or updated information will be recorded in the originally  completed eDC.
The investigator will submit any  updated SAE data to GSK within the designated 
reporting time fram es.
2016N275057_03 CONFIDENTIA L
204958
68Reporting of SA Es to GSK
SAE reporting to GSK via paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Medical Monitor.
In rare circumstances and in the absence of facsimile equipment, not ification by  
telephone is acceptable, with a cop y of the SAE data collection tool sent by 
overnight mail
Initial notification via the telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated repo rting time frames.
Contacts for SAE receipt can be found at this beginning of the protocol on the 
Sponsor/Medical Monitor Contact Information page.
2016N275057_03 CONFIDENTIA L
204958
6912.4. Appendix 4 -Definition of and Procedures for Documenting 
Medical Device Incidents
Definitions of a Medic al Device Incident
The detection and documentation procedures described in this protocol apply  to all GSK 
medical devices provided for use in the stud y (see Section 6.2 for the list of GSK medical 
devices).
Medi cal Device Incident Definition:
Incident –Any malfunction or deterioration in the characteristics and/or performance 
of a device, as well as any  inadequacy  in the labeling or the instructions for use 
which, directl y or indirectly , might lead to or might h ave led to the death of a 
patient/user/other persons or to a serious deterioration in their state of health.
Not all incidents lead to death or serious deterioration in health.  The non- occurrence 
of such a result might have been due to other fortunate cir cumstances or to the 
intervention of health care personnel.
It is sufficient that:
an incident associated with a device happened and
the incident was such that, if it occurred again, might lead to death or a serious 
deterioration in health.
A serious deter ioration in state of health can include:
life-threatening illness
permanent impairment of body  function or permanent damage to a bod y 
structure
a condition necessitating medical or surgical intervention to prevent one of the 
above 
fetal distress, fetal de ath or any  congenital abnormality  or birth defects
Examples of incidents
a patient, user, care giver or professional is injured as a result of a medical device 
failure or its misuse
a patient’s treatment is interrupted or compromised by  a medical device fa ilure
misdiagnosis due to medical device failure leads to inappropriate treatment
a patient’s health deteriorates due to medical device failure
2016N275057_03 CONFIDENTIA L
204958
70Documenting Medical Device Incidents
Medical Device Incident Documenting:
Any medical device incident occurring during the study  will be documented in 
the subject’s medical records, in accordance with the investigator’s normal 
clinical practice, and on the appropriate form.
For incidents fulfilling the definition of an AE or an SAE, the appropriate 
AE/SAE  form will be completed as described in Appendix 3 .
The form will be completed as thoroughl y as possible and signed b y the 
investigator before transmittal to GSK.
It is very  important that the investigator provides his/her asses sment of causality  
to the medical device provided by  GSK at the time of the initial report, and 
describes an y corrective or remedial actions taken to prevent recurrence of the 
incident.
A remedial action is an y action other than routine maintenance or serv icing of a 
device where such action is necessary to prevent recurrence of an incident. This 
includes any amendment to the design to prevent recurrence.
2016N275057_03 CONFIDENTIA L
204958
7112.5. Appendix 5 -Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in FRP and Collection of P regnancy  
Information
Definition of post menopausal female
Post menopausal female is defined as:
Females 60 years of age or older
Menopause is the phase associated with complete cessation of menstrual cycles 
and implies the loss of reproductive potential by ovarian failure. This ty pically  
occurs around 50 years of age, although it may  occur earlier or later. A practical 
definition accepts menopause after 1 year without menses with an appropriate 
clinical profile, e.g., age appropriate, >45 years, in the abse nce of hormone 
replacement therap y (HRT) or medical suppression of the menstrual cy cle (e.g., 
leuprolide treatment).
In questionable cases for women < 60 years of age, a blood sample with 
simultaneous follicle stimulating hormone and estradiol falling into the 
central laboratory ’s postmenopausal reference range is confirmatory  (these 
levels need to be adjusted for specific laboratories/assay s) [Kronenberg , 
2008; Strauss , 2004]. 
Females under 60 years of age, who are on HRT and wish to continue, and 
whose menopausal status is in doubt, are required to use a highl y effective 
method to avoid pregnancy , as outlined in the protocol. Otherwise, they  
must discontinue HRT to allow co nfirmation of post -menopausal status 
prior to study  enrolment. For most forms of HRT, at least 2 to 4 weeks 
will elapse between the cessation of therap y and the blood draw; this 
interval depends on the type and dosage of HRT. Following confirmation 
of thei r post -menopausal status, they  can resume use of HRT during the 
study  without use of a highl y effective method to avoid pregnancy. If 
laboratory  values for FSH and estradiol are drawn and the results do not 
confirm menopause on a potential subject that otherwise met the 
specifications for being post -menopausal defined above without question, 
the subject may  still enrol in the study as a FNRP if approved by  the GSK 
Medical Monitor and the safet y physician.
Modified List of Highly Effective Methods for Avoidi ng Pregnancy  in 
Females of Reproductive Potential (FRP)
The list does not apply  to FRP with same sex partners or for subjects who are and will 
continue to be abstinent from penile-vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle. Periodic abstinence (e.g. calendar, 
ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not acceptable 
methods of contraception.
2016N275057_03 CONFIDENTIA L
204958
72Contraceptive subdermal implant
Intrauterine device or intrauterine s ystem
Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011]
Injectable progestogen [ Hatcher , 2011]
Contraceptive vaginal ring [ Hatcher , 2011]
Percutaneous contraceptive patches [ Hatcher , 2011]
Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for t hat subject 
[Hatcher , 2011]. The documentation on male sterility  can come from the site 
personnel’s: review of subject’s medical records, medical examination and/or semen 
analysis, or medical history  interview provi ded b y her or her partner.
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use thes e methods of contraception.
Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to GSK within 2 
weeks of learning of a subject's pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to GSK.  Generall y, follow-up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, an y pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  the investigator, will be reported to GSK 
as described in Appendix 3 . While the investigator is not obligated to actively  seek 
this i nformation in former study participants, he or she may learn of an SAE through 
spontaneous reporting.
2016N275057_03 CONFIDENTIA L
204958
7312.6. Appendix 6 -Anaphy laxis Criteria
Hypersensitivity  reactions will be monitored using the diagnostic criteria for anaphy laxis 
as outlined by  the Joint NIA ID/FAAN Second Symposium on Anaph ylaxis [ Sampson
, 
2006].  The criteria do not make a distinction based on underl ying mechanism. These 
criteria are summarized as follows:
Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips -
tongue -uvula), and at least one of the following:
Respiratory  compromise (e.g., dy spnea, wheeze
-bronchospasm, stridor, reduced peak 
expiratory  flow [PEF], hy poxemia)
Reduced blood pressure (BP) or associated s ymptoms of end -organ d ysfunction (e.g., 
hypotonia [collapse], sy ncope, incontinence)
Two or more of the following that occur rapidly  after exposure to a likel y allergen for 
that pat ient (minutes to several hours):
Involvement of the skin -mucosal tissue (e.g., generalized hives, itch -flush, swollen 
lips-tongue -uvula)
Respiratory  compromise (e.g., dy spnea, wheeze- bronchospasm, stridor, reduced PEF, 
hypoxemia)
Reduced BP or associated s ymptoms (e.g., h ypotonia [collapse], syncope, 
incontinence)
Persistent gastrointestinal sy mptoms (e.g., cramp y abdominal pain, vomiting)
Reduced BP after exposure to known allergen for that patient (minutes to several hours):
Infants and children: low sy stolic BP (age specific) or greater than 30% decrease in 
systolic BP
Adults: sy stolic BP of less than 90 mm Hg or greater than 30% decrease from that 
person’s baseline.
2016N275057_03 CONFIDENTIA L
204958
7412.7. Appendix 7 -Inspection of the A utoinjector
Injection Assessment -Autoinjector
Was the full dose successfully 
administered?Yes, injection successful
                No, injection not successful (please complete the questions below 1)
No, injection not attempted
Were there any observations with respect to the user tasks that ind icate that the 
full dose has not been administered? Check all that apply.
- Incorrect injection site selected, record location below
        ________________________________________
- Pen was not pushed all the way down and held
- Pen pulled away before end of injection (i.e., before the second click, 
orbefore the plunger stops moving and the yellow indicator fills the 
window, orbefore holding for a total of 15seconds)
- Evidence of liquid leaking from injection site (i.e. potentially indicating 
a premature lift or a wet injection) 
- Other (please specify below)
         ________________________________________
Were there any observations with respect to the device that indicate that the full 
dose has not been dispensed? Check all that apply.
- Pen leaking
- Componen ts broken / cracked
- Cannot push the needle guard down to activate (i.e., force required is 
too high)
- Pen does not activate (after pressing needle guard down)
- Delivery stops before end of injection (yellow indicator stopped before 
reaching bottom of inspect ion window)
- Other (please specify below)
         ________________________________________
Footnote 1 refers to the Autoinjector Error / Failure Reporting Form, Appendix 8 .
Failure in either of these two events req uires the appropriate form to be completed.
HCP should review the user tasks in completing the injection, the device and the 
packaging and complete Appendix 8 to capture any issues.
2016N275057_03 CONFIDENTIA L
204958
7512.8. Appendix 8 -Auto injector Error/Failure reporting form
AUTOINJECTOR ERROR / FAILURE REPORTING FORM
Please write clearl y using BLOCK CAPITAL LETTERS.
Please complete form within 24 hours of autoinjector failure/user error at site and submit 
to GSK
Primary  Investigator: Protocol #:
204958
Site Contact for I P Accountability : Site #:
Contact Phone (print clearly ): Subject #:
E-mail (print clearly ): Autoinjector Kit #:
Site Address: Date Dispensed:
Date Returned:
Has the autoinjector been used by  the HCP?       ___ No             ___ Yes
(Considered a 
biohazard.)  
Was there an AE or SAE associated with this failure/error?      ___ No             ___ Yes 
If yes, please enter the eDC AE sequence number:______________________
Description of user error:
Which of the following user errors appl y? Tick all that apply :
__   Did not check Expiration Date
__   I ncorrect preparation or incorrect choice of injection site
__   Did not check product solution
__   Clear cap not removed from autoinjector
2016N275057_03 CONFIDENTIA L
204958
76__   Autoinjector not properly  activated on injection site (e.g., needle guard  not flush 
with skin)
__   Autoinjector used upside down
__   Autoinjector pulled away  before end of injection (i.e., before y ellow indicator 
stopped moving)
__   Did not check inspection window for y ellow indica tor
__   Other (please specify  below).
Description of failure:
Reason for Autoinjector Failure. Tick all that apply:
__   Autoinjector leaking
__   Components  broken/cracked/missing
__   I nspection window not clear
__   Cannot remove clear cap
__   Be nt needle
__   L iquid is cloudy , discoloured or contains large particles
__   Cannot push the needle guard down to activate (i.e., force is too high)
__   Autoinjector does not activate (after pressing needle guard down)
__   Delivery  stops before end of i njection (y ellow indicator stopped before reaching 
bottom of inspection window)
__   Other (please specify  below)
Description of failure:
2016N275057_03 CONFIDENTIA L
204958
77Packaging Failure. Tick all that apply :
__   Device damaged
__   Packaging damaged or can’t read label
__   Securit y seal was broken
__   Autoinjector missing from kit
__   Other (please specify  below)
Failure Outcome (check one):
    Subject received no dose
   Subject received a partial dose
       ( ensure date used is captured above)Resolution (check one) :
    Replacement autoinjector 
provided
    Dose omitted
    Subject Withdrawn
Replacement Autoinjector Dispensed Date: Kit # of Replacement Autoinjector:
Instructions f or further processing: Please fax or email completed Form to The GSK 
Pen Failure Processing Team at  or email address.  Please contact 
your study  monitor with any  questions or for troubleshooting.  Maintain the Form and in 
the patients’ r ecords. You may  be contacted further concerning the malfunctioned 
autoinjector.
PPD
2016N275057_03 CONFIDENTIA L
204958
7812.9. Appendix 9 -Inspection of the Safety  Syringe
Injection Assessment –Safety Syringe
Was the full dose successfully 
administered?Yes, injection successful
                No, injection not successful (please complete the questions below 1)
No, injection not attempted
Were there any observations with respect to the user tasks that indicate that 
the full dose has not been administered? Check all that apply.
- Incorrec t injection site selected, record location below
        ________________________________________
- Needle not fully inserted into site
- Plunger not slowly pushed down
- Plunger not pushed all the way down until the stopper reaches the 
bottom of the syringe
- Thumb not moved up, plunger not risen and needle guard not 
activated
- Evidence of liquid leaking from injection site (i.e. potentially indicating 
a premature lift or a wet injection)
- Other (please specify below)
        ________________________________________
Were there any observations with respect to the device that indicate that the 
full dose has not been dispensed? Check all that apply.
- Syringe leaking
- Components broken / cracked
- Cannot push the plunger rod down (i.e., required force is too high)
- Other (p lease specify below)
         ________________________________________
Footnote 1 refers to the Safet y Syringe Error / Failure Reporting Form, Appendix 10 .
Failure in either of these two events requires the appro priate form to be completed. 
HCP should review the user tasks in completing the injection, the device and the 
packaging and complete Appendix 10 to capture any issues.
2016N275057_03 CONFIDENTIA L
204958
7912.10. Appendix 10 -Safety  Syringe Error/ Failure repo rting form
SAFTEY SYRINGE ERROR / FAILURE REPORTI NG FORM
Please write clearl y using BLOCK CAPITAL LETTERS.
Please complete form within 24 hours of safet y syringe failure/user error at site and 
submit to GSK
Primary  Investigator: Protocol #:
204958
Site Co ntact for I P Accountability : Site #:
Contact Phone (print clearly ): Subject #:
E-mail (print clearly ): Safety  Syringe Number:
Site Address: Date Dispensed:
Date Returned:
Has the safety  syringe been used b y the HCP?       ___ No             ___ Yes
(Considered a biohazard.)  
Was there an AE or SAE associated with this failure/error?      ___ No             ___ Yes 
If yes, please enter the eDC AE sequence number:______________________
Description of user error:
Which of the following u ser errors appl y? Tick all that apply :
__   Did not check Expiration Date
__   I ncorrect preparation or incorrect choice of injection site
__   Did not check product solution
2016N275057_03 CONFIDENTIA L
204958
80__   Needle shield not removed from safety  syringe
__   Safet y syringe pulled aw ay before end of injection (i.e., before the plunger all the 
way down)
__   Did not check inspection window for white plunger
__   Other (please specify  below).
Description of failure:
Reason for Safet y Syringe Failure. Tick all that apply:
__   Safe ty Syringe leaking
__   Components  broken/cracked
__   I nspection window not clear
__   Cannot remove needle shield 
__   Bent needle
__   L iquid is cloudy , discoloured or contains large particles
__   Cannot push the plunger rod down (i.e., force is too high)
__   Other (please specify  below)
Description of failure:
Packaging Failure. Tick all that apply :
2016N275057_03 CONFIDENTIA L
204958
81__   Device damaged
__   Packaging damaged or can’t read label
__   Security  seal was broken
__   Other (please specify  below)
Failure Outcome ( check one):
    Subject received no dose
   Subject received a partial dose
       ( ensure date used is captured above)Resolution (check one) :
    Replacement safet y syringe 
provided
    Dose omitted
    Subject Withdrawn
Replacement Safet y Syringe Dispensed Date: Replacement Safet y Syringe 
Number:
Instructions for further processing: Please fax or email completed Form to The GSK 
Pen Failure Processing Team at  or email address.  Please contact 
your study  monitor with any  questions or for troubleshooting.  Maintain the Form and in 
the subjects’ records. You may  be contacted further concerning the malfunctioned safet y 
syringe.
PPD
2016N275057_03 CONFIDENTIA L
204958
8212.11. Appendix 11 -Coun try Specific Requirements
No country -specific requirements exist.
2016N275057_03 CONFIDENTIA L
204958
8312.12. Appendix 12 -Protocol A mendment C hanges 01
Where this amendment Applies
This amendment applies across an y site that will be used in the study.
Summary of Amendment Changes with Rationale
Change in medical monitor sponsor page. Removal of Cardiovascular and deaths events 
Section 7.3.1.4.
Update to the content of the error/failure reporting forms to reflect consistency  with other 
data captured in similar studies.
List of Specific Changes
Title: Medical Monitor Page
PREVIOUS TEXT
MEDICA LMONITOR /SPONSOR INFORM ATIONPAGE
Medical Monitor/SAE Contact Information: 
Role Nam e Day Tim e Phone Number and 
email addressAfter -hours 
Phone/Cell/
Pager 
NumberSite Address
Primary 
Medical 
Monitor Telephone: Cell: GlaxoSmithKline
Upper Merion
709 Sw edeland Road, 
King of Prussia, PA –
19406, USA
Secondary 
Medical 
Monitor Telephone: Cell: GlaxoSmithKline
5 Moore Drive, PO Box 
13398, Research 
Triangle Park (RTP), 
NC 27709 -3398, USA
SAE contact  
information Medical 
monitor as 
above Telephone: Cell: GlaxoSmithKline
5 Moore Drive, PO Box 
13398, Research 
Triangle Park (RTP), 
NC 27709 -3398, USA 
PPD
PPD
PPD
PPD
PPD
PPD
PP
D
PPD
PPD
PPD
PP
D
PPD
PPD
PPD
PP
D
PPD
PPD
2016N275057_03 CONFIDENTIA L
204958
84REVISED TEXT
MEDICA L MONITOR/SPONSOR INFORM ATION PA GE
Medical Monitor/SAE Contact Information: 
Role Nam e Day Tim e Phone Number and 
email addressAfter -hours 
Phone/C ell/
Pager 
NumberSite Address
Primary 
Medical 
Monitor Telephone: Cell: GlaxoSmithKline
Upper Merion
709 Sw edeland Road, 
King of Prussia, PA –
19406, USA
Secondary 
Medical 
Monitor Telephone: Cell: GlaxoSmithKline
5 Moore Drive, PO Box 
13398, Research 
Triangle Park (RTP), 
NC 27709 -3398, USA
SAE contact  
information Medical 
monitor as 
above Telephone: Cell: GlaxoSmithKline
Upper Merion
709 Sw edeland Road, 
King of Prussia, PA –
19406, USA
Title: Updated Exploratory endpoints in Section 3 Objectives and Endpoints
PREVI OUS TEXT
Exploratory
To evaluate mepolizumab 
pharmacod ynamic effects on blood 
eosinophil count following a single SC 
dose of the liquid drug product in  
safet y syringe or the liquid drug 
product in autoinjector in comparison 
with the ly ophilised drug productRatio to baseline in b lood eosinophil 
count over time
To evaluate safet y syringe and 
autoinjector use & functionalityDevice functionality questions 
PPD
PPD
PPD
PPD
PP
D
PPD
PPD
PPD
PPD
PP
D
PPD
PPD
PPD
PPD
PP
D
PPD
PPD
2016N275057_03 CONFIDENTIA L
204958
85REVI SED TEXT
Exploratory
To evaluate mepolizumab 
pharmacod ynamic effects on blood 
eosinophil count following a single SC 
dose of the liquid drug product in  
safet y syringe or the liquid drug 
product in autoinjector in comparison 
with the ly ophilised drug productRatio to baseline in blood eosinophil 
count over time
To evaluate safet y syringe and 
autoinjector use & function alityUser and device errors 
Title:  Updated Section 5.4.1 Withdrawal from the study  
PREVIOUS TEXT
5.4.1 Withdrawal from the study
A subject must be discontinued if any of the following criteria are met:
Withdrawal of consent
Lost to follow -up
A subjec t will also be withdrawn from the study, in consultation with the medical 
monitor and principal investigator, if an y of the following criteria are met:
Laboratory  parameters: Clinically  important changes in laboratory  parameters 
identified
Pregnancy : Posit ive pregnancy  test (see Section 7.3.2). Pregnancy  and pregnancy  
outcomes of subjects exposed to mepolizumab will be followed.
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y visit:
The site m ust attempt to contact the subject and re- schedule the missed visit as soon 
as possible. 
The site must counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should contin ue in 
the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or designee 
must make every  effort to regain contact with the subject (where possible, 3 
telephone calls and if necessary  a certified letter to the subject’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the subject’s medical record. 
2016N275057_03 CONFIDENTIA L
204958
86Should the subject continue to be unreachable, only then will he/she be considered to 
have withdrawn from the study  with a pri mary  reason of “Lost to Follow -up”. 
If a subject withdraws from the study then the assessments in the time and events 
table under Section 7.1  Day 85 Withdraw (WD) column must be performed. A 
reason for the withdrawal from the study must be captured in th e eDC.
REVISED TEXT
Section 5.4.1
If a subject withdraws from the study then the assessments in the time and events 
table under Section 7.1  Day 85 Withdraw (WD) column must be performed. A 
reason for the withdrawal from the study must be captured in the eDC.
A subject must be discontinued if any of the following criteria are met:
Withdrawal of consent
Lost to follow -up
A subject will also be withdrawn from the study , in consultation with the medical 
monitor and principal investigator, if an y of the following criteria are met:
Laboratory  parameters: Clinically  important changes in laboratory  parameters 
identified
Pregnancy : Positive pregnancy  test (see Section 7.3.2). Pregnancy  and pregnancy  
outcomes of subjects exposed to mepolizumab will be followed.
Thefollowing actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact the subject and re- schedule the missed visit as soon 
as possible. 
The site must counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in 
the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or designee 
must make every  effort t o regain contact with the subject (where possible, 3 
telephone calls and if necessary  a certified letter to the subject’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the subject’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered to 
have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
Title: Update to title of procedure name in Section 7.1 Time and events table
2016N275057_03 CONFIDENTIA L
204958
87PREVIOUS TEXT :
Autoinjector 
and safety 
syringe 
functionality 
assessmentX HCP reported. 
See Section 
7.4.4. 
REVISED TEXT:
Autoinjector 
and safety 
syringe 
user/device 
error 
assessmentX HCP reported. 
See Section 
7.4.4. 
Title: Rem oval of Cardiovascular and death events section
PREVIOUS TEXT
7.3.1.4 Cardiovascular and Death Events
7.3.1.4.1 Cardiovascular events
Cardiovascular -related AEs and SAEs that will require the investigator to complete event 
specific pages in the eDC sy stem are listed in Section 12.3, Appendix 3.
Cardiovascular events information should be recorded on the corresponding eDC pages 
within one week of when the AE/SAE(s) are first reported.  Please refer to Appendix 3 
for timelines for reporting AE/SAEs.
7.3.1.4. 2 Deaths
In addition, all deaths will require completion of a specific death data collection page in 
the eDC sy stem.  The death data collection page in the eDC system includes questions 
regarding cardiovascular (including sudden cardiac death) and non -cardiovascular death.
Death information should be recorded on the death eDC sy stem page within one week of 
when the death is first reported.
Please refer to Section 12.3, Appendix 3 for timelines for reporting SAEs.
2016N275057_03 CONFIDENTIA L
204958
88REVISED TEXT
7.3.1.4 Cardiovascular and Dea th Events
No cardiovascular or death events will be captured in this study as this is a healthy 
volunteer study.
Title: Section 9.6.1 Update to the name of the device error
PREVIOUS TEXT
9.6.1 Exploratory Analyses
Ratio to baseline in blood eosinophil coun t will be log transformed and compared 
between treatments using a mixed model repeated measures anal ysis, adjusting for the 
covariates of baseline blood eosinophil count (log scale) and baseline weight (log scale). 
Time point and injection site (upper arm, abdomen, thigh) will be fitted as a categorical 
variables with the effect of treatment group and baseline blood eosinophil count vary ing 
at each timepoint (i.e. timepoint- by-baseline and timepoint- by-treatment interactions will 
be included in the model).
Device functionality questionnaire will be summarized using appropriate descriptive 
statistics.
REVISED TEXT
9.6.1 Exploratory Analyses
Ratio to baseline in blood eosinophil count will be log transformed and compared 
between treatments using a mixed model repeated measures anal ysis, adjusting for the 
covariates of baseline blood eosinophil count (log scale) and baseline weight (log scale). 
Time point and injection site (upper arm, abdomen, thigh) will be fitted as a categorical 
variables with the effect of treatment group and baseline blood eosinophil count vary ing 
at each timepoint (i.e. timepoint- by-baseline and timepoint- by-treatment interactions will 
be included in the model).
User and device errors will be summarized using appropriate descriptive statis tics.
Title: Removal of Definition of Cardiovascular Events 
PREVIOUS TEXT
Appendix 3 -Definition of and Procedures for Recording, Evaluating, Follow -Up 
and Reporting of Adverse Events
2016N275057_03 CONFIDENTIA L
204958
89Definition of Cardiovascular Events
Cardiovascular Events (CV) Defin ition:
Investigators will be required to fill out the specific CV event page of the eDC for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/s troke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
REVISED TEXT
This section has been removed from Appendix 3. 
Title: Update to Appendix 7 I nspection of the autoinjector
PREVIOUS TEXT
Appendix 7 -Inspection of the A utoinjector
Footnote 1 refers to the Autoinjector Error / Failure Reporting Form, Appendix 8 .
Failure in either of these two events requires the appropriate form to be completed. 
2016N275057_03 CONFIDENTIA L
204958
90REVISED TEXT
Appendix 7 -Inspection of the A utoinjector
Injection Assessment -Autoinjector
Was the full dose successfully 
administered?Yes, injection successful
                No, injection not successful (please complete the questions below 1)
No, injection not attemp ted
Were there any observations with respect to the user tasks that indicate that the 
full dose has not been administered? Check all that apply.
- Incorrect injection site selected, record location below
        ________________________________________
- Penwas not pushed all the way down and held
- Pen pulled away before end of injection (i.e., before the second click, 
orbefore the plunger stops moving and the yellow indicator fills the 
window, orbefore holding for a total of 15seconds)
- Evidence of liquid leaking from injection site (i.e. potentially indicating 
a premature lift or a wet injection) 
- Other (please specify below)
         ________________________________________
Were there any observations with respect to the device that indicate that the ful l 
dose has not been dispensed? Check all that apply.
- Pen leaking
- Components broken / cracked
- Cannot push the needle guard down to activate (i.e., force required is 
too high)
- Pen does not activate (after pressing needle guard down)
- Delivery stops before end of injection (yellow indicator stopped before 
reaching bottom of inspection window)
- Other (please specify below)
         ________________________________________
Footnote 1 refers to the Autoinjector Error / Failure Reporting Form, Appendix 8 .
Failur e in either of these two events requires the appropriate form to be completed. 
2016N275057_03 CONFIDENTIA L
204958
91HCP should review the user tasks in completing the injection, the device and the 
packaging and complete Appendix 8 to capture any issues.
Title: Update to Appendix 8 Auto injec tor Error/Failure reporting form 
PREVIOUS TEXT
AUTOINJECTOR ERROR / FAILURE REPORTING FORM
Please write clearl y using BLOCK CAPITAL LETTERS.
Please complete form within 24 hours of autoinjector failure/user error at site and submit 
to GSK
Primary  Investig ator: Protocol #:
204958
Site Contact for I P Accountability : Site #:
Contact Phone (print clearly ): Subject #:
E-mail (print clearly ): Autoinjector Kit #:
Site Address: Date Dispensed:
Date Returned:
Has the autoinjector been used by  the HCP?       ___ No             ___ Yes
(Considered a 
biohazard.)  
Was there an AE or SAE associated with this failure/error?      ___ No             ___ Yes 
If yes, please enter the eDC AE sequence number:______________________
Description of user error :
Which of the following user errors appl y? Tick all that apply :
__   Did not check Expiration Date
2016N275057_03 CONFIDENTIA L
204958
92__   I ncorrect preparation or incorrect choice of injection site
__   Did not check product solution
__   Clear cap not removed from autoinjector
__   Autoinjector not properly  activated on injection site (e.g., needle guard  not flush 
with skin)
__   Autoinjector used upside down
__   Autoinjector pulled away  before end of injection (i.e., before y ellow indicator 
stopped moving)
__   Did not check inspect ion window for y ellow indicator
__   Other (please specify  below).
Description of failure:
Reason for Autoinjector Failure. Tick all that apply:
__   Autoinjector leaking
__   Components  broken/cracked/missing
__   I nspection window not clear
__   Cannot remove clear cap
__   Bent needle
__   L iquid is cloudy , discoloured or contains large particles
__   Cannot push the needle guard down to activate (i.e., force is too high)
__   Autoinjector does not activate (after pressing needle guard down)
__   De livery  stops before end of injection (y ellow indicator stopped before reaching 
bottom of inspection window)
__   Other (please specify  below)
Description of failure:
2016N275057_03 CONFIDENTIA L
204958
93Packaging Failure. Tick all that apply :
__   Device damaged
__   Packaging damaged or can’t read label
__   Security  seal was broken
__   Autoinjector missing from kit
__   Other (please specify  below)
Failure Outcome (check one):
    Subject received no dose
   Subject received a partial dose
       ( ensure date used is captured above)Resolution (check one) :
    Replacement autoinjector 
provided
    Dose omitted
    Subject Withdrawn
Replacement Autoinjector Dispensed Date: Kit # of Replacement Au toinjector:
Instructions for further processing: Please fax or email completed Form to The GSK Pen 
Failure Processing Team at  or email address.  Please contact y our 
study  monitor with any  questions or for troubleshooting.  Maintain the Form and in the 
patients’ records. You may  be contacted further concerning the malfunctioned 
autoinjector.
REVISED TEXT
AUTOINJECTOR (PEN) ERROR / FA ILURE REPORTING FORM
Please write clearly using BLOCK CA PITA L LETTERS.
Please complete form within 24 hours of pen failure/user error at site and 
submit to GSK
via email to 
Primary Investigator: Protocol #:
204958
Site Contact for IP A ccountability: Site #:
Contact Phone (print clearly): Subject #:
PPD
PPD
2016N275057_03 CONFIDENTIA L
204958
94E-mail (print clearly):
Site Address: Date Dispensed:
Date Returned:
Has the pen been used by the patient?       ___ No             ___ Yes
(Considered a 
biohazard.)  
Was there an A E or SA E associated with this failure/error?      ___ No             ___ Yes 
If yes, please enter the eCRF A E sequence number:______________________
Please provide overall description of user/pen/packaging error/failure:
Which of the following user errors apply? Tick all that apply:
__   Did not check expiration date
__   Did not chec k product solution
__   Incorrect choice of injection site
__   Clear needle cap not removed from autoinjector
__   Took longer than 5 minutes before carrying out the injection
__   Pen not properly activated on injection site (e.g., needle guard  not flus h with skin)
__   Pen used upside down
__   Pen not pressed and held down
__   Pen pulled away before end of injection (i.e., before the second click, or before the yellow indicator
stopped moving, or 
        before holding for a total of 15seconds )
__   Evidence of liquid leaking from injection site (i.e. potentially indicating a premature lift or a 
wet injection)
2016N275057_03 CONFIDENTIA L
204958
95__   Other (please specify below ).
Description of other user error:
Reason for pen failure. Tick all that apply:
__  Pen leaking
__  Compon ents broken / cracked
__   Liquid is cloudy, discoloured or contains large particles
__   Cannot remove clear needle cap
__   Bent needle
__   Cannot push the needle guard down to activate (i.e., force required is too high)
__   Pen does not activate (afte r pressing needle guard down)
__   Delivery stops before end of injection ( yellow indicator stopped before reaching bottom of 
inspection window)
__   Other (please specify below )
Description of other pen failure:
Packaging failure. Tick all that apply:
__  Device damaged
__  Packaging damaged or can’t read label
__   Security seal was broken
__   Pen missing from kit
__   Other (please specify below )
2016N275057_03 CONFIDENTIA L
204958
96Descript ion of other packaging failure:
Error/failure outcome (check one):
   Subject received no dose
   Subject received a partial dose
       (ensure date used is captured above)Resolution (check one) :
    Replacement pen provided
    Dose omitted
    Subject w ithdrawn
Replacement Pen Dispensed Date:
Instructions for further processing: Please email completed Form to The GSK 
Pen Failure Processing Team at   Please 
contact your study monitor with any questions or for troubleshoo ting.  Maintain 
the Form and in the subjects’ records. You may be contacted further concerning 
the malfunctioned pen.
Title: Appendix 9: I nspection of the safet y syringe
PREVIOUS TEXT
Appendix 9 -Inspection of the Safety  Syringe
Footnote 1 refers to the Safet y Syringe Error / Failure Reporting Form, Appendix 10 .
Failure in either of these two events requires the appropriate form to be completed. 
PPD
2016N275057_03 CONFIDENTIA L
204958
97REVISED TEXT
Appendix 9 - Inspection of the Safet y Syringe
Injection Assessment –Syringe
Was the full d ose successfully 
administered?Yes, injection successful
                No, injection not successful (please complete the questions below 1)
No, injection not attempted
Were there any observations with respect to the user tasks that indicate that the 
full dose has not been administered? Check all that apply.
- Incorrect injection site selected, record location below
        ________________________________________
- Needle not fully inserted into site
- Plunger not slowly pushed down
- Plunger not pushed all the way down until the stopper reaches the 
bottom of the syringe
- Thumb not moved up, plunger not risen and needle guard not 
activated
- Evidence of liquid leaking from injection site (i.e. potentially indicating 
a premature lift or a wet injection)
- Other (please specify below)
        ________________________________________
Were there any observations with respect to the device that indicate that the full 
dose has not been dispensed? Check all that apply.
- Syringe leaking
- Components broken / cracked
- Cannot push the plunger rod down (i.e., required force is too high)
- Other (please specify below)
         ________________________________________
Footnote 1 refers to the Safet y Syringe Error / Failure Reporting Form, Appendix 10 .
Failure in either o f these two events requires the appropriate form to be completed. 
HCP should review the user tasks in completing the injection, the device and the 
packaging and complete A ppendix 10 to capture any issues.
2016N275057_03 CONFIDENTIA L
204958
98Title: Update to Appendix 10 Safety Syringe Error/ Failure reporting form
PREVIOUS TEXT
SAFTEY SYRINGE ERROR / FAILURE REPORTI NG FORM
Please write clearl y using BLOCK CAPITAL LETTERS.
Please complete form within 24 hours of safet y syringe failure/user error at site and 
submit to GSK
Primary Investigator: Protocol #:
204958
Site Contact for IP Accountability: Site #:
Contact Phone (print clearly): Subject #:
E-mail (print clearly): Safety Syringe Number:
Site Address: Date Dispensed:
Date Returned:
Has the safety syringe been used by the HCP?       ___ No             ___ Yes
(Considered a biohazard.)  
Was there an AE or SAE associated w ith this failure/error?      ___ No             ___ Yes 
If yes, please enter the eDC AE sequence number:______________________
Description of user error:
Which of the following user errors apply? Tick all that apply:
__   Did not check Expiration Date
__   Incorrect preparation or incorrect choice of injection site
__   Did not check product solution
__   Needle shield not removed from safety syringe
__  Safety syringe pulled away before end of injection (i.e., before the plunger all the way dow n)
2016N275057_03 CONFIDENTIA L
204958
99__   Did not check inspection window  for white plunger
__   Other (please specify below).
Description of failure:
Reason for Safety Syringe Failure. Tick al l that apply:
__   Safety Syringe leaking
__   Components  broken/cracked
__   Inspection w indow  not clear
__   Cannot remove needle shield 
__   Bent needle
__   Liquid is cloudy, discoloured or contains large particles
__   Cannot push the plunger rod do wn (i.e., force is too high)
__   Other (please specify below)
Description of failure:
Packaging Failure. Tick all that apply:
__   Device damaged
__   Packaging damaged or can’t read label
__   Security seal was broken
__   Other (please specify below )
Failure Outcome (check one):
    Subject received no dose
   Subject received a partial dose
       ( ensure date used is captured above)Resolution (check one) :
    Replacement safety syringe provi ded
    Dose omitted
    Subject Withdrawn
2016N275057_03 CONFIDENTIA L
204958
100Replacement Safety Syringe Dispensed Date: Replacement Safety Syringe Number:
Instructions for further processing: Please fax or email completed Form to The GSK 
Pen Failure Processing Team at  or email address.  Please contact 
your study  monitor with any  questions or for troubleshooting.  Maintain the Form and in 
the subjects’ records. You may  be contacted further concerning the malfunctioned safet y 
syringe .
REVISED TEXT
SYRINGE ERROR / FA ILURE REPORTING FORM
Please write clearly using BLOCK CA PITA L LETTERS.
Please complete form within 24 hours of safety  syringe failure/user error at 
site and submit to GSK
via email to 
Primary Investigator: Protocol #:
204958
Site Contact for IP A ccountability: Site #:
Contact Phone (print clearly): Subject #:
E-mail (print clearly):
Site A ddress: Date Dispensed:
Date Returned:
Has the safety syringe been used by the patient?       ___ No             ___ Yes
(Considered a biohazard.)  
Was there an A E or SA E associated with this failure/error?      ___ No             ___ Yes 
If yes, please enter the eCRF A E sequence number:______________________
Please provide overall de scription of user/pen/packaging error/failure:
PPD
PPD
2016N275057_03 CONFIDENTIA L
204958
101Which of the following user errors apply? Tick all that apply:
__   Did not check expiration date
__   Did not check product solution
__   Incorrect choice of injection site
__   Needle cap not removed from syringe
__   Took longer than 5 minutes before carrying out the injection
__   Did not pinch the skin around the injection site
__   Did not insert the entire needle into the pinched area at an angle
__   Syringe pulled away before end of injection (i.e., before the plunger is pushed all the way 
down)
__   Did not move thumb up to allow the plunger to rise and activate the needle guard
__   Evidence of liquid leaking from injection site (i.e. potentially indicating a premature lift or a 
wet injection)
__   Other (please specify below ).
Description of other user error:
Syringe failure. Tick all that apply:
__  Syringe leaking
__   Components broken / cracked
__   Liquid is cloudy, discoloured or contains large particles
__   Cannot remove needle cap 
__  Bent needle
__   Cannot push the plunger rod down (i.e., required force is too high)
2016N275057_03 CONFIDENTIA L
204958
102__   Other (please specify below )
Description of other syringe failure:
Packaging failure. Tick all that apply:
__   Device damaged
__   Packaging damaged or can’t re ad label
__   Security seal was broken
__   Syringe missing from kit
__   Other (please specify below )
Description of other packaging failure:
Error/failure outcome (check one):
   Subject received no dose
   Subject received a partial dose
       (ensure date used is captured above)Resolution (check one) :
    Replacement syringe provided
    Dose omitted
    Subject withdrawn
Replacement Syringe Dispensed Dat e:
Instructions for further processing: Please email completed Form to The GSK 
Safety Syringe Failure Processing Team at 
  Please contact your study monitor 
with any questions or for troubleshooting.  Maintain the For m and in the subjects’ 
records. You may be contacted further concerning the malfunctioned safety 
syringe.
PPD
2016N275057_03 CONFIDENTIA L
204958
10312.13. Appendix 13 -Protocol A mendment C hanges 02
Where this amendment Applies
This amendment applies across an y site that will be used in the study.
Summa ry of Amendment Changes with Rationale
Minor changes overall to the document listing changes to abbreviations and text.
List of Specific Changes
Title: Cover page authors list
PREVIOUS TEXT
 
REVI SED TEXT
Author (s):  
Title: Investigator Protocol Agree ment page
PREVIOUS TEXT
For protocol number 
REVI SED TEXT
For protocol number 204958
Title: Abbreviations updated for Subcutaneous in Overall Design page 10 and 17
PREVIOUS TEXT
All treatments will be administered subcutaneous by a health care professiona l (HCP).  
The study  will compare the pharmacokinetics and safet y of mepolizumab administered as 
a liquid drug product in two different devices with the reconstituted l yophilised drug 
product. 
PPD
PPD
2016N275057_03 CONFIDENTIA L
204958
104REVI SED TEXT
All treatments will be administered SC by ahealth care professional (HCP).  The stud y 
will compare the pharmacokinetics and safet y of mepolizumab administered as a liquid 
drug product in two different devices with the reconstituted ly ophilised drug product.
Title: Abbreviations updated for Confidence In terval in Analysis 
PREVIOUS TEXT
Analysis
Point estimates and associated two -sided 90% confidence intervals will be constructed 
for the differences between the test and reference treatments on the log escale; these will 
be back -transformed to provide point estimates and two- sided 90% CIs for the ratio of 
each of the test treatments to the reference treatment on the original scale.
REVISED TEXT
Analysis
Point estimates and associated two -sided 90% confidence intervals (CI) will be 
constructed for the differ ences between the test and reference treatments on the log e
scale; these will be back -transformed to provide point estimates and two -sided 90% CIs 
for the ratio of each of the test treatments to the reference treatment on the original scale.
Title: Abbre viations updated for Confidence Interval in Analysis
PREVIOUS TEXT
Clinical data for mepolizumab administered b y the IV,SC or I M routes in a variet y of 
eosinophilic conditions is summarised in the Investigators’ Brochure (GlaxoSmithKline 
Document Number C M2003/00010/10).
REVISED TEXT
Clinical data for mepolizumab administered b y the intravenous (IV), SC or IM routes in 
a variet y of eosinophilic conditions is summarised in the I nvestigators’ Brochure 
(GlaxoSmithKline Document Number CM 2003/00010/10).
2016N275057_03 CONFIDENTIA L
204958
105Title: Updated text in Section 4.3 Type and Number of subjects
PREVIOUS TEXT
Additional subjects may  be enrolled if deemed appropriate to ensure at least 216 
completed subjects at the discretion of the Sponsor in consultation with the I nvestigator. 
(i.e. complete Day  85 visit). See Table 1
REVISED TEXT
Additional subjects may  be enrolled if deemed appropriate to ensure at least 216 
completed subjects at the discretion of the Sponsor in consultation with the I nvestigator. 
(i.e. complete Day  85 visit). See Table 1 below.
Title: Section 4.5 Dose Justification
PREVIOUS TEXT
A single mepolizumab dose of 100 mg administered subcutaneous is selected in this 
study  as it is the approved therapeutic dose in severe asthma and the anticipated 
therapeutic dose in COPD.
REVISED TEXT
A single mepolizumab dose of 100 mg administered SC is selected in this study  as it is 
the approved therapeutic dose in severe asthma and the anticipated therapeutic dose in 
chronic obstructive pulmonary disease (COPD).
Title: Section 4.6 Benefit:Risk Assessment
PREVIOUS TEXT
Summaries of findings from both clinical and non-clinical studies conducted with 
mepolizumab (SB -240563) ly ophilised drug product can be found in the Investigator’s 
Brochur e.
REVISED TEXT
Summaries of findings from both clinical and non -clinical studies conducted with 
mepolizumab (SB -240563) ly ophilised drug product can be found in the Investigator’s 
Brochure (IB).
2016N275057_03 CONFIDENTIA L
204958
106Title: Section 4.6.1 Risk Assessment –Text that has changed is included in the table 
below.
PREVIOUS TE XT
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Investigational Product (IP)  
Risk of Sy stemic  
Reactions, including 
allergic reactionsBiopharmaceutical products 
administered 
subcutaneously may elicit 
systemic (e.g. 
hypersensitivity ) and local 
site reactions.Daily  monitoring of serious 
adverse events (SAEs) by 
medical monitor; regular 
systematic review of 
adverse events /SAE data 
from ongoing studies b y the 
GSK study  team and/or 
safet y review team. 
Injection site reactions Daily  monitoring of serious 
adverse events (SAEs) by 
medical monitor; regular 
systematic review of 
adverse events /SAE data 
from ongoing studies b y 
GSK study  team and/or 
safet y review team. 
REVISED TEXT
Potential Risk of Clin ical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Investigational Product (IP)  
Risk of Sy stemic  
Reactions, including 
allergic reactionsBiopharmaceutical products 
administered SCmay elicit 
systemic (e.g. 
hypersensitivity ) and local 
site reactions.Daily  monitoring of serious 
adverse events (SAEs) by 
medical monitor; regular 
systematic review of 
AE/SAE data from ongoing 
studies by  the 
GlaxoSmithKline (GSK)
2016N275057_03 CONFIDENTIA L
204958
107Potential Risk of Clin ical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
study  team and/or safety  
review team. 
Injection site reactions Daily monitoring of serious 
adverse events (SAEs) by 
medical monitor; regular 
systematic review of 
AE/SAE data from ongoing 
studies by  GSK study  team 
and/or safet y review team. 
Title: Section 6.2 Medical Devices
PREVIOUS TEXT
The instructions for use (IFU ) of these injection devices are provided in the study 
reference manual ( SRM ).The instructions were developed and optimized as a result of 
formative human factors studies.
REVISED TEXT
The instructions for use (IFU) of these injection devices are provided in the SRM . The
instructions were developed and optimized as a result of formative human factors studies.
Title: Section 6.6 Preparation/Handling/Storage/Accountability
PREVIOUS TEXT
A description of the methods and materials required for mepolizumab wil l be detailed in 
the Study  Reference Manual ( SRM ).
REVISED TEXT
A description of the methods and materials required for mepolizumab will be detailed in 
the SRM.
2016N275057_03 CONFIDENTIA L
204958
108Title: Section 6.11.1 Caffeine, Alcohol and Tobacco
PREVI OUS TEXT
During the dosing session, subjects will abstain from ingesting caffeine -or xanthine -
containing products (e.g., coffee, tea, cola drinks and chocolate) for 12 hours prior to 
the start of dosing until collection of the final pharmacokinetic and/or 
pharmacodynamic  sample of the sessi on and prior to all out -patient visits. 
During the dosing session, subjects will abstain from alcohol for 24 hours prior to the 
start of dosing until collection of the final pharmacokinetic and/or 
pharmacodynamic sample of the session and prior to all out -patient visits. 
REVI SED TEXT
During the dosing session, subjects will abstain from ingesting caffeine -or xanthine -
containing products (e.g., coffee, tea, cola drinks and chocolate) for 12 hours prior to 
the start of dosing until collection of the final pharmacokinetic and/or PDsample of 
the session and prior to all out -patient visits. 
During the dosing session, subjects will abstain from alcohol for 24 hours prior to the 
start of dosing until collection of the final pharmacokinetic and/or PDsample ofthe 
session and prior to all out -patient visits. 
Title: Section 7. Study Assessments and procedures
PREVIOUS TEXT
The timing and number of planned study  assessments, including safet y, 
pharmacokinetic, pharmacodynamic /biomarker assessments may be altered
during the course of the study  based on newly  available data (e.g., to obtain data 
closer to the time of peak plasma concentrations) to ensure appropriate 
monitoring. 
REVISED TEXT
The timing and number of planned study  assessments, including safet y, 
pharmacokinetic , PD/biomarker assessments may  be altered during the course of 
the study  based on newly available data (e.g., to obtain data closer to the time of 
peak plasma concentrations) to ensure appropriate monitoring. 
2016N275057_03 CONFIDENTIA L
204958
109Title: 7.6.2 Sample Analysis
PREV IOUS TEXT
Plasma analy sis will be performed under the control of PTS, GlaxoSmithKline ,the 
details of which will be included in the Study  Reference Manual (SRM).
Once the plasma has been anal yzed for mepolizumab any  remaining plasma may  be 
analyzed for o ther compound -related material and the results reported under a separate 
PTS, GlaxoSmithKline   protocol.
REVISED TEXT
Plasma analy sis will be performed under the control of PTS , GSK, the details of which 
will be included in the Study  Reference Manual (SRM). Concentrations of mepolizumab 
will be determined in plasma samples using the currentl y approved bioanalytical 
methodology . Raw data will be archived at the bioanal ytical site (detailed in the SRM).
Once the plasma has been anal yzed for mepolizumab any remaining plasma may  be 
analyzed for other compound -related material and the results reported under a separate 
PTS, GSK protocol.
Title: Section 9.1 Hypotheses
PREVIOUS TEXT
For AUC (0-t), AUC (0-∞)and Cmax, point estimates and corresponding two- sided 90% 
confidence intervals will be constructed for the ratio of the geometric mean of each test 
treatment to the geometric mean of the reference treatment, μ(test)/μ(reference). No 
formal h ypothesi s will be tested. However, interpretation of the comparability  of the 
autoinjector and safet y syringe with the reconstituted ly ophilised drug product will be 
guided b y a two -sided 90% confidence interval for μ(test)/μ(reference) in the range 
(0.80, 1.25) f or AUC (0-t),AUC (0-∞)and Cmax.
REVISED TEXT
For AUC (0-t), AUC (0-∞)and Cmax, point estimates and corresponding two- sided 90% 
confidence intervals (CI) willbe constructed for the ratio of the geometric mean of each 
test treatment to the geometric mean of the reference treatment, μ(test)/μ(reference). No 
formal h ypothesis will be tested. However, interpretation of the comparability of the 
autoinjector and safet y syringe with the reconstituted ly ophilised drug product will be 
guided b y a two -sided 90 % CIfor μ(test)/μ(reference) in the range (0.80, 1.25) for 
AUC (0-t),AUC (0-∞)and Cmax.
2016N275057_03 CONFIDENTIA L
204958
110Title: Section 9.2 Sample Size considerations
PREVI OUS TEXT
Variability  estimates for AUC (0-∞), AUC (0-τ) and Cmax for mepolizumab were considered 
from three studies; SB -24056 3/017, SB -240563/018 and MEA114092. Only  data from 
treatment groups with subcutaneous administration of mepolizumab in the upper arm, 
abdomen or thigh, for doses of 125mg and 250mg across the 3 studies was considered. 
REVI SED TEXT
Variability  estimates for AUC (0-∞), AUC (0-τ) and Cmax for mepolizumab were considered 
from three studies; SB -240563/017, SB -240563/018 and MEA114092. Only  data from 
treatment groups with SCadministration of mepolizumab in the upper arm, abdomen or 
thigh, for doses of 125mg and 250mg across the 3 studies was considered. 
Title: 9.5 Primary Analyses
PREVI OUS TEXT
Point estimates and associated two -sided 90% confidence intervals will be constructed 
for the differences between the test and reference treatments on the log escale; these will 
be back -transformed to provide point estimates and two -sided 90% CIs for the ratio of 
each of the test treatments to the reference treatment on the original scale.
REVI SED TEXT
Point estimates and associated two -sided 90% CI swill be constructed for the differences 
between the test and reference treatments on the log escale; these will be back-
transformed to provide point estimates and two -sided 90% CIs for the ratio of each of the 
test treatments to the reference treatment on the original scale.
Title: Section 11 References
PREVIOUS TEXT
Hatcher RA , Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, Policar MS , 
editors . Contraceptive Technology . 20thedition. Atlanta, Georgia: Ardent Media, Inc., 
2011: 50. Table 3-2.
REVISED TEXT
Hatcher RA , Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D , et.al., editors . 
Contraceptive Technology . 20thedition. Atlanta, Georgia: Ardent Media, Inc., 2011: 50.
Table 3-2.
2016N275057_03 CONFIDENTIA L
204958
111Title: Section: 12.1 Appendix 1 –Abbreviations and Trademarks
The following abbreviat ions and trademarks have been removed from this version 
of the protocol.
AD Atopic Dermatitis
CPAP Continous Positive Airway Pressure
LABA Long acting beta 2 agonist
LTRA Leuketriene receptor anatagonist
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
ADVAIR™ Chiron RIBA
SAS
2016N275057_03 CONFIDENTIA L
204958
11212.14. Appendix 14 -Protocol A mendment C hanges 03
Where this amendment Applies
This amendment applies across an y site that will be used in the study .
Specific Change
Title: Section 7.3.1.4. Cardiovascular and Death Events
PREVIOUS TEXT
No cardiovascular or death events will be captured in this study  as this is a healthy  
volunteer study .
REVISED TEXT
Section has been deleted from the docum ent
Specific Change
Title: Section 7.3.1.4. Cardiovascular and Death Events
PREVIOUS TEXT
Section 7.3.1.4. Cardiovascular and Death Events
No cardiovascular or death events will be captured in this study  as this is a healthy  
volunteer study .
REVISED TEXT
*Upon deletion of Section 7.3.1.4 “Cardiovascular and Death Events” the subsequent 
Section 7.3.1.5 becomes 7.3.1.4 , no change to body of text
Section 7.3.1.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  the investigator to GSK of SAEs related to study  treatment (even 
for non -interventional post -marketing studies) is essential so that legal obligations and 
ethical responsibilities towards the safet y of subjects and the safety of a product under 
clinical investigation are met. 
GSK has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  GSK will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators.
2016N275057_03 CONFIDENTIA L
204958
113Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and GSK pol icy and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from GSK will file it with 
the IB and will notify  the IRB/IEC, if appropriate according to local requirements.